[S02DA03, antipyrine, The risk or severity of hyperkalemia can be increased when Antipyrine is combined with Fluspirilene.]
[L04AA27, fingolimod, Fluspirilene may increase the bradycardic activities of Fingolimod.]
[M03AB01, succinylcholine, The risk or severity of adverse effects can be increased when Succinylcholine is combined with Fluspirilene.]
[J01EC02, sulfadiazine, The risk or severity of hypoglycemia can be increased when Fluspirilene is combined with Sulfadiazine.]
[J01EC01, sulfamethoxazole, The risk or severity of hypoglycemia can be increased when Fluspirilene is combined with Sulfamethoxazole.]
[S01AB02, sulfisoxazole, The risk or severity of QTc prolongation can be increased when Sulfisoxazole is combined with Fluspirilene.]
[M01AB02, sulindac, The risk or severity of hyperkalemia can be increased when Sulindac is combined with Fluspirilene.]
[N05AL01, sulpiride, Fluspirilene may increase the antipsychotic activities of Sulpiride.]
[N03AX03, sulthiame, The risk or severity of adverse effects can be increased when Fluspirilene is combined with Sulthiame.]
[A10BB04, glibornuride, The risk or severity of hypoglycemia can be increased when Fluspirilene is combined with Glibornuride.]
[A10BC01, glymidine, The risk or severity of hypoglycemia can be increased when Fluspirilene is combined with Glymidine.]
[M01AX04, apazone, The risk or severity of hyperkalemia can be increased when Fluspirilene is combined with Azapropazone.]
[L02BA01, tamoxifen, The risk or severity of QTc prolongation can be increased when Tamoxifen is combined with Fluspirilene.]
[N05CD07, temazepam, The risk or severity of adverse effects can be increased when Temazepam is combined with Fluspirilene.]
[L01CB02, teniposide, Teniposide may increase the neurotoxic activities of Fluspirilene.]
[R03CC03, terbutaline, The risk or severity of QTc prolongation can be increased when Terbutaline is combined with Fluspirilene.]
[N07XX06, tetrabenazine, The risk or severity of adverse effects can be increased when Fluspirilene is combined with Tetrabenazine.]
[S01HA03, tetracaine, The risk or severity of adverse effects can be increased when Fluspirilene is combined with Tetracaine.]
[N05AE05, lurasidone, The risk or severity of adverse effects can be increased when Fluspirilene is combined with Lurasidone.]
[A04AD10, dronabinol, Dronabinol may increase the central nervous system depressant (CNS depressant) activities of Fluspirilene.]
[N04BC07, apomorphine, The risk or severity of adverse effects can be increased when Apomorphine is combined with Fluspirilene.]
[L04AX02, thalidomide, Fluspirilene may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[L01XX41, eribulin, The risk or severity of QTc prolongation can be increased when Eribulin is combined with Fluspirilene.]
[R06AD03, thiethylperazine, The risk or severity of adverse effects can be increased when Thiethylperazine is combined with Fluspirilene.]
[N05CA19, thiopental, The metabolism of Fluspirilene can be increased when combined with Thiopental.]
[N05AB08, thioproperazine, The risk or severity of hypotension can be increased when Thioproperazine is combined with Fluspirilene.]
[N05AC02, thioridazine, The risk or severity of QTc prolongation can be increased when Fluspirilene is combined with Thioridazine.]
[N05AF04, thiothixene, The risk or severity of adverse effects can be increased when Thiothixene is combined with Fluspirilene.]
[C01BB04, aprindine, Aprindine may increase the arrhythmogenic activities of Fluspirilene.]
[N05AL03, tiapride, The risk or severity of adverse effects can be increased when Fluspirilene is combined with Tiapride.]
[N02AX01, tilidine, The risk or severity of adverse effects can be increased when Fluspirilene is combined with Tilidine.]
[S01ED01, timolol, The risk or severity of adverse effects can be increased when Fluspirilene is combined with Timolol.]
[A10BB05, tolazamide, The risk or severity of hypoglycemia can be increased when Fluspirilene is combined with Tolazamide.]
[M02AX02, tolazoline, The risk or severity of hypotension can be increased when Tolazoline is combined with Fluspirilene.]
[V04CA01, tolbutamide, The risk or severity of hypoglycemia can be increased when Fluspirilene is combined with Tolbutamide.]
[M02AA21, tolmetin, The risk or severity of hyperkalemia can be increased when Tolmetin is combined with Fluspirilene.]
[M03BX04, tolperisone, The risk or severity of adverse effects can be increased when Fluspirilene is combined with Tolperisone.]
[N02AX02, tramadol, The risk or severity of serotonin syndrome can be increased when Fluspirilene is combined with Tramadol.]
[N06AF04, tranylcypromine, The risk or severity of adverse effects can be increased when Tranylcypromine is combined with Fluspirilene.]
[N06AX05, trazodone, The risk or severity of QTc prolongation can be increased when Trazodone is combined with Fluspirilene.]
[C03DB02, triamterene, The risk or severity of hyperkalemia can be increased when Triamterene is combined with Fluspirilene.]
[N05CD05, triazolam, The risk or severity of adverse effects can be increased when Triazolam is combined with Fluspirilene.]
[A03AB12, mepenzolate, Fluspirilene may increase the central nervous system depressant (CNS depressant) activities of Mepenzolate.]
[N05AB06, trifluoperazine, The risk or severity of hypotension can be increased when Trifluoperazine is combined with Fluspirilene.]
[N05AD02, trifluperidol, The risk or severity of adverse effects can be increased when Fluspirilene is combined with Trifluperidol.]
[N05AA05, triflupromazine, Fluspirilene may increase the central nervous system depressant (CNS depressant) activities of Triflupromazine.]
[N04AA01, trihexyphenidyl, Fluspirilene may increase the central nervous system depressant (CNS depressant) activities of Trihexyphenidyl.]
[A03AA05, trimebutine, Fluspirilene may increase the arrhythmogenic activities of Trimebutine.]
[S01ED04, metipranolol, Fluspirilene may increase the arrhythmogenic activities of Metipranolol.]
[R06AD01, trimeprazine, The risk or severity of adverse effects can be increased when Alimemazine is combined with Fluspirilene.]
[N03AC02, trimethadione, Trimethadione may increase the arrhythmogenic activities of Fluspirilene.]
[J01EA01, trimethoprim, The risk or severity of hyperkalemia can be increased when Trimethoprim is combined with Fluspirilene.]
[N06AA06, trimipramine, The risk or severity of adverse effects can be increased when Trimipramine is combined with Fluspirilene.]
[R06AX07, triprolidine, The risk or severity of adverse effects can be increased when Triprolidine is combined with Fluspirilene.]
[A03BB01, butylscopolamine, Fluspirilene may increase the central nervous system depressant (CNS depressant) activities of Butylscopolamine.]
[J01FA08, troleandomycin, The metabolism of Fluspirilene can be decreased when combined with Troleandomycin.]
[N06AX24, vilazodone, The risk or severity of adverse effects can be increased when Vilazodone is combined with Fluspirilene.]
[N06AX02, tryptophan, The risk or severity of adverse effects can be increased when Tryptophan is combined with Fluspirilene.]
[C09CA09, azilsartan medoxomil, The risk or severity of hyperkalemia can be increased when Fluspirilene is combined with Azilsartan medoxomil.]
[M03AA02, tubocurarine, Fluspirilene may increase the neuromuscular blocking activities of Tubocurarine.]
[L01EX04, vandetanib, The risk or severity of QTc prolongation can be increased when Fluspirilene is combined with Vandetanib.]
[A10BH05, linagliptin, The metabolism of Fluspirilene can be decreased when combined with Linagliptin.]
[J05AP03, boceprevir, The metabolism of Fluspirilene can be decreased when combined with Boceprevir.]
[J05AP02, telaprevir, The metabolism of Fluspirilene can be decreased when combined with Telaprevir.]
[J05AG05, rilpivirine, The risk or severity of QTc prolongation can be increased when Rilpivirine is combined with Fluspirilene.]
[N03AX21, ezogabine, The risk or severity of adverse effects can be increased when Fluspirilene is combined with Ezogabine.]
[R03AC18, indacaterol, The risk or severity of QTc prolongation can be increased when Indacaterol is combined with Fluspirilene.]
[C08DA01, verapamil, Verapamil may increase the arrhythmogenic activities of Fluspirilene.]
[N06AX09, viloxazine, The metabolism of Fluspirilene can be decreased when combined with Viloxazine.]
[L01CA02, vincristine, Vincristine may increase the neurotoxic activities of Fluspirilene.]
[B01AA03, warfarin, The risk or severity of adverse effects can be increased when Fluspirilene is combined with Warfarin.]
[N05AF05, zuclopenthixol, The risk or severity of QTc prolongation can be increased when Fluspirilene is combined with Zuclopenthixol.]
[J05AE02, indinavir, The metabolism of Fluspirilene can be decreased when combined with Indinavir.]
[N03AX14, levetiracetam, The risk or severity of adverse effects can be increased when Levetiracetam is combined with Fluspirilene.]
[L01EC01, vemurafenib, The risk or severity of QTc prolongation can be increased when Fluspirilene is combined with Vemurafenib.]
[L01ED01, crizotinib, Crizotinib may increase the bradycardic activities of Fluspirilene.]
[M05BA06, ibandronic acid, The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Fluspirilene.]
[J01MA13, trovafloxacin, The risk or severity of QTc prolongation can be increased when Fluspirilene is combined with Trovafloxacin.]
[N05AE04, ziprasidone, The risk or severity of QTc prolongation can be increased when Fluspirilene is combined with Ziprasidone.]
[G03AC10, drospirenone, The risk or severity of hyperkalemia can be increased when Drospirenone is combined with Fluspirilene.]
[N02BA01, aspirin, The risk or severity of hyperkalemia can be increased when Acetylsalicylic acid is combined with Fluspirilene.]
[L01EJ01, ruxolitinib, Ruxolitinib may increase the bradycardic activities of Fluspirilene.]
[G04BD07, tolterodine, Fluspirilene may increase the central nervous system depressant (CNS depressant) activities of Tolterodine.]
[C07AB03, atenolol, Atenolol may increase the arrhythmogenic activities of Fluspirilene.]
[J02AC03, voriconazole, The metabolism of Fluspirilene can be decreased when combined with Voriconazole.]
[M03AC04, atracurium, Fluspirilene may increase the neuromuscular blocking activities of Atracurium.]
[S01FA01, atropine, Atropine may increase the arrhythmogenic activities of Fluspirilene.]
[G04BE10, avanafil, The serum concentration of Avanafil can be increased when it is combined with Fluspirilene.]
[M03BX01, baclofen, Baclofen may increase the central nervous system depressant (CNS depressant) activities of Fluspirilene.]
[A08AA11, lorcaserin, The risk or severity of adverse effects can be increased when Lorcaserin is combined with Fluspirilene.]
[G04BD12, mirabegron, The risk or severity of QTc prolongation can be increased when Mirabegron is combined with Fluspirilene.]
[V03AX03, cobicistat, The metabolism of Fluspirilene can be decreased when combined with Cobicistat.]
[J05AJ02, elvitegravir, The metabolism of Fluspirilene can be decreased when combined with Elvitegravir.]
[L02BB04, enzalutamide, The serum concentration of Fluspirilene can be decreased when it is combined with Enzalutamide.]
[A06AX04, linaclotide, The therapeutic efficacy of Linaclotide can be decreased when used in combination with Fluspirilene.]
[A02AA05, magnesium silicate, The risk or severity of hypotension can be increased when Magnesium silicate is combined with Fluspirilene.]
[L01EX05, regorafenib, Fluspirilene may increase the bradycardic activities of Regorafenib.]
[N05CA04, barbital, The metabolism of Fluspirilene can be increased when combined with Barbital.]
[C01AA01, acetyldigitoxin, Acetyldigitoxin may increase the arrhythmogenic activities of Fluspirilene.]
[J05AE04, nelfinavir, The metabolism of Fluspirilene can be decreased when combined with Nelfinavir.]
[S01GA07, brimonidine, Brimonidine may increase the central nervous system depressant (CNS depressant) activities of Fluspirilene.]
[N04BD02, rasagiline, The risk or severity of adverse effects can be increased when Rasagiline is combined with Fluspirilene.]
[C08CA13, lercanidipine, Lercanidipine may increase the arrhythmogenic activities of Fluspirilene.]
[A03FA09, mosapride, The risk or severity of adverse effects can be increased when Fluspirilene is combined with Mosapride.]
[N06DA02, donepezil, The risk or severity of adverse effects can be increased when Donepezil is combined with Fluspirilene.]
[N03AX22, perampanel, Perampanel may increase the central nervous system depressant (CNS depressant) activities of Fluspirilene.]
[L04AA29, tofacitinib, Fluspirilene may increase the bradycardic activities of Tofacitinib.]
[N02CC03, zolmitriptan, The risk or severity of adverse effects can be increased when Zolmitriptan is combined with Fluspirilene.]
[R06AC06, thonzylamine, Fluspirilene may increase the central nervous system depressant (CNS depressant) activities of Thonzylamine.]
[G04BD10, darifenacin, Fluspirilene may increase the central nervous system depressant (CNS depressant) activities of Darifenacin.]
[N01AA01, ethyl ether, The risk or severity of adverse effects can be increased when Fluspirilene is combined with Diethyl ether.]
[H01CB05, pasireotide, The risk or severity of QTc prolongation can be increased when Pasireotide is combined with Fluspirilene.]
[J04AK05, bedaquiline, The risk or severity of QTc prolongation can be increased when Fluspirilene is combined with Bedaquiline.]
[C04AX11, bencyclane, Fluspirilene may increase the arrhythmogenic activities of Bencyclane.]
[A10BH04, alogliptin, The risk or severity of hypoglycemia can be increased when Fluspirilene is combined with Alogliptin.]
[C03AA01, bendroflumethiazide, Bendroflumethiazide may increase the bradycardic activities of Fluspirilene.]
[L04AX06, pomalidomide, The risk or severity of adverse effects can be increased when Fluspirilene is combined with Pomalidomide.]
[N02BA10, benorilate, The risk or severity of hyperkalemia can be increased when Fluspirilene is combined with Benorilate.]
[N05AD07, benperidol, The risk or severity of adverse effects can be increased when Fluspirilene is combined with Benperidol.]
[A10BK02, canagliflozin, The risk or severity of hypoglycemia can be increased when Fluspirilene is combined with Canagliflozin.]
[J01MA15, gemifloxacin, The risk or severity of QTc prolongation can be increased when Gemifloxacin is combined with Fluspirilene.]
[A12CC09, magnesium orotate, The risk or severity of hypotension can be increased when Magnesium orotate is combined with Fluspirilene.]
[S01AE07, moxifloxacin, The risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Fluspirilene.]
[A06AX06, tegaserod, The risk or severity of serotonin syndrome can be increased when Tegaserod is combined with Fluspirilene.]
[A10AE05, insulin detemir, The risk or severity of hypoglycemia can be increased when Fluspirilene is combined with Insulin detemir.]
[R02AD01, benzocaine, The risk or severity of adverse effects can be increased when Benzocaine is combined with Fluspirilene.]
[A10BX05, pramlintide, The risk or severity of hypoglycemia can be increased when Fluspirilene is combined with Pramlintide.]
[M01AH01, celecoxib, The risk or severity of hyperkalemia can be increased when Celecoxib is combined with Fluspirilene.]
[N02CC02, naratriptan, The risk or severity of adverse effects can be increased when Naratriptan is combined with Fluspirilene.]
[A12CC05, magnesium aspartate, The risk or severity of hypotension can be increased when Magnesium aspartate is combined with Fluspirilene.]
[N04AC01, benztropine, The risk or severity of adverse effects can be increased when Fluspirilene is combined with Benzatropine.]
[L01EC02, dabrafenib, The serum concentration of Fluspirilene can be decreased when it is combined with Dabrafenib.]
[R02AX03, benzydamine, The risk or severity of hyperkalemia can be increased when Fluspirilene is combined with Benzydamine.]
[P03AX06, benzyl alcohol, The risk or severity of adverse effects can be increased when Fluspirilene is combined with Benzyl alcohol.]
[N06AX28, levomilnacipran, The risk or severity of adverse effects can be increased when Fluspirilene is combined with Levomilnacipran.]
[C08EA02, bepridil, Bepridil may increase the arrhythmogenic activities of Fluspirilene.]
[A10BJ03, lixisenatide, The risk or severity of hypoglycemia can be increased when Fluspirilene is combined with Lixisenatide.]
[N06AX26, vortioxetine, The risk or severity of adverse effects can be increased when Vortioxetine is combined with Fluspirilene.]
[N03AF04, eslicarbazepine, The risk or severity of adverse effects can be increased when Fluspirilene is combined with Eslicarbazepine.]
[J05AP05, simeprevir, The metabolism of Fluspirilene can be decreased when combined with Simeprevir.]
[N03AG04, vigabatrin, The risk or severity of adverse effects can be increased when Vigabatrin is combined with Fluspirilene.]
[A10BK01, dapagliflozin, The risk or severity of hypoglycemia can be increased when Fluspirilene is combined with Dapagliflozin.]
[C07AB04, acebutolol, Acebutolol may increase the arrhythmogenic activities of Fluspirilene.]
[N05CH03, tasimelteon, The risk or severity of adverse effects can be increased when Fluspirilene is combined with Tasimelteon.]
[A16AA07, metreleptin, The metabolism of Fluspirilene can be increased when combined with Metreleptin.]
[S01ED02, betaxolol, Betaxolol may increase the arrhythmogenic activities of Fluspirilene.]
[A10BJ04, albiglutide, The risk or severity of hypoglycemia can be increased when Fluspirilene is combined with Albiglutide.]
[L01ED02, ceritinib, Fluspirilene may increase the bradycardic activities of Ceritinib.]
[A03BA03, hyoscyamine, Hyoscyamine may increase the arrhythmogenic activities of Fluspirilene.]
[B01AA07, acenocoumarol, The risk or severity of adverse effects can be increased when Fluspirilene is combined with Acenocoumarol.]
[N01AX05, alfaxalone, The risk or severity of adverse effects can be increased when Fluspirilene is combined with Alfaxalone.]
[A10BK03, empagliflozin, The risk or severity of hypoglycemia can be increased when Fluspirilene is combined with Empagliflozin.]
[R03AC19, olodaterol, The risk or severity of QTc prolongation can be increased when Olodaterol is combined with Fluspirilene.]
[D11AA01, glycopyrronium, Fluspirilene may increase the central nervous system depressant (CNS depressant) activities of Glycopyrronium.]
[N05CM19, suvorexant, Fluspirilene may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.]
[A16AX10, eliglustat, The risk or severity of QTc prolongation can be increased when Fluspirilene is combined with Eliglustat.]
[N05AA04, acepromazine, The risk or severity of hypotension can be increased when Acepromazine is combined with Fluspirilene.]
[A06AB04, phenolphthalein, The therapeutic efficacy of Phenolphthalein can be decreased when used in combination with Fluspirilene.]
[A10BJ05, dulaglutide, The risk or severity of hypoglycemia can be increased when Fluspirilene is combined with Dulaglutide.]
[N04AA02, biperiden, Fluspirilene may increase the central nervous system depressant (CNS depressant) activities of Biperiden.]
[A06AG02, bisacodyl, The therapeutic efficacy of Bisacodyl can be decreased when used in combination with Fluspirilene.]
[B01AA01, dicumarol, The risk or severity of adverse effects can be increased when Fluspirilene is combined with Dicoumarol.]
[N06AX11, mirtazapine, Fluspirilene may increase the serotonergic activities of Mirtazapine.]
[L01EX08, lenvatinib, The risk or severity of QTc prolongation can be increased when Fluspirilene is combined with Lenvatinib.]
[L01XH03, panobinostat, The risk or severity of QTc prolongation can be increased when Fluspirilene is combined with Panobinostat.]
[A03AA09, difemerine, Fluspirilene may increase the central nervous system depressant (CNS depressant) activities of Difemerine.]
[B01AA11, tioclomarol, The risk or severity of adverse effects can be increased when Fluspirilene is combined with Tioclomarol.]
[C01EB17, ivabradine, Fluspirilene may increase the bradycardic activities of Ivabradine.]
[A07DA06, eluxadoline, The risk or severity of serotonin syndrome can be increased when Fluspirilene is combined with Eluxadoline.]
[N05AX16, brexpiprazole, The risk or severity of hypotension can be increased when Brexpiprazole is combined with Fluspirilene.]
[G02CX02, flibanserin, The risk or severity of adverse effects can be increased when Fluspirilene is combined with Flibanserin.]
[A06AD03, magnesium peroxide, The risk or severity of hypotension can be increased when Magnesium peroxide is combined with Fluspirilene.]
[N05AX15, cariprazine, The risk or severity of adverse effects can be increased when Fluspirilene is combined with Cariprazine.]
[A10BF01, acarbose, The risk or severity of hypoglycemia can be increased when Fluspirilene is combined with Acarbose.]
[M02AA25, aceclofenac, The risk or severity of hyperkalemia can be increased when Fluspirilene is combined with Aceclofenac.]
[M01AB11, acemetacin, The risk or severity of hyperkalemia can be increased when Fluspirilene is combined with Acemetacin.]
[S01EC01, acetazolamide, The risk or severity of adverse effects can be increased when Acetazolamide is combined with Fluspirilene.]
[A10AE06, insulin degludec, The risk or severity of hypoglycemia can be increased when Fluspirilene is combined with Insulin degludec.]
[N05AB07, acetophenazine, The risk or severity of adverse effects can be increased when Acetophenazine is combined with Fluspirilene.]
[J02AC05, isavuconazole, The metabolism of Fluspirilene can be decreased when combined with Isavuconazole.]
[A10BB31, acetohexamide, The risk or severity of hypoglycemia can be increased when Fluspirilene is combined with Acetohexamide.]
[G04CA01, alfuzosin, The risk or severity of hypotension can be increased when Alfuzosin is combined with Fluspirilene.]
[N05CA05, aprobarbital, The risk or severity of adverse effects can be increased when Aprobarbital is combined with Fluspirilene.]
[M01AE16, alminoprofen, The risk or severity of hyperkalemia can be increased when Fluspirilene is combined with Alminoprofen.]
[N03AX23, brivaracetam, The risk or severity of adverse effects can be increased when Fluspirilene is combined with Brivaracetam.]
[L01XX52, venetoclax, The metabolism of Fluspirilene can be decreased when combined with Venetoclax.]
[N05BA08, bromazepam, The risk or severity of adverse effects can be increased when Bromazepam is combined with Fluspirilene.]
[N04BC01, bromocriptine, The risk or severity of adverse effects can be increased when Bromocriptine is combined with Fluspirilene.]
[A03AX08, alverine, The risk or severity of adverse effects can be increased when Alverine is combined with Fluspirilene.]
[R06AB01, brompheniramine, The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Fluspirilene.]
[N06AA19, amineptin, The risk or severity of adverse effects can be increased when Amineptine is combined with Fluspirilene.]
[C08CA01, amlodipine, Amlodipine may increase the arrhythmogenic activities of Fluspirilene.]
[N05AX17, pimavanserin, Fluspirilene may increase the neurotoxic activities of Pimavanserin.]
[N06BX11, aniracetam, The risk or severity of adverse effects can be increased when Aniracetam is combined with Fluspirilene.]
[N01BB01, bupivacaine, The risk or severity of adverse effects can be increased when Bupivacaine is combined with Fluspirilene.]
[C07AA19, bupranolol, Fluspirilene may increase the arrhythmogenic activities of Bupranolol.]
[N07BC01, buprenorphine, Fluspirilene may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[L02AE01, buserelin, The risk or severity of QTc prolongation can be increased when Buserelin is combined with Fluspirilene.]
[N05BE01, buspirone, The risk or severity of adverse effects can be increased when Buspirone is combined with Fluspirilene.]
[L01XX27, arsenic trioxide, The risk or severity of QTc prolongation can be increased when Fluspirilene is combined with Arsenic trioxide.]
[N06DA03, rivastigmine, Rivastigmine may increase the bradycardic activities of Fluspirilene.]
[P01BE02, artemether, The risk or severity of QTc prolongation can be increased when Fluspirilene is combined with Artemether.]
[N02AF01, butorphanol, The risk or severity of adverse effects can be increased when Butorphanol is combined with Fluspirilene.]
[J01MA09, sparfloxacin, The risk or severity of QTc prolongation can be increased when Fluspirilene is combined with Sparfloxacin.]
[R06AX09, azatadine, The risk or severity of QTc prolongation can be increased when Azatadine is combined with Fluspirilene.]
[S01GX07, azelastine, Fluspirilene may increase the central nervous system depressant (CNS depressant) activities of Azelastine.]
[S01AA26, azithromycin, The risk or severity of QTc prolongation can be increased when Azithromycin is combined with Fluspirilene.]
[A06AX07, plecanatide, The therapeutic efficacy of Plecanatide can be decreased when used in combination with Fluspirilene.]
[L01EF02, ribociclib, The metabolism of Fluspirilene can be decreased when combined with Ribociclib.]
[A07EC04, balsalazide, The risk or severity of hyperkalemia can be increased when Balsalazide is combined with Fluspirilene.]
[N07XX16, deutetrabenazine, The risk or severity of adverse effects can be increased when Fluspirilene is combined with Deutetrabenazine.]
[N02BF02, pregabalin, The therapeutic efficacy of Fluspirilene can be increased when used in combination with Pregabalin.]
[N03AX30, beclamide, The risk or severity of adverse effects can be increased when Fluspirilene is combined with Beclamide.]
[C09AA07, benazepril, The risk or severity of hyperkalemia can be increased when Benazepril is combined with Fluspirilene.]
[A10BX06, benfluorex, The risk or severity of hypoglycemia can be increased when Fluspirilene is combined with Benfluorex.]
[S01HA02, benoxinate, The risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Fluspirilene.]
[G04BA03, calcium chloride, The therapeutic efficacy of Fluspirilene can be decreased when used in combination with Calcium chloride.]
[J01XX08, linezolid, The risk or severity of serotonin syndrome can be increased when Linezolid is combined with Fluspirilene.]
[J05AE09, tipranavir, The metabolism of Fluspirilene can be decreased when combined with Tipranavir.]
[D11AX03, calcium gluconate, The therapeutic efficacy of Fluspirilene can be decreased when used in combination with Calcium gluconate.]
[L01EX10, midostaurin, The metabolism of Fluspirilene can be decreased when combined with Midostaurin.]
[N04BD03, safinamide, The risk or severity of adverse effects can be increased when Fluspirilene is combined with Safinamide.]
[J01MA23, delafloxacin, The risk or severity of QTc prolongation can be increased when Delafloxacin is combined with Fluspirilene.]
[D01AC10, bifonazole, The therapeutic efficacy of Bifonazole can be increased when used in combination with Fluspirilene.]
[P03AC02, bioallethrin, Fluspirilene may increase the arrhythmogenic activities of Bioallethrin.]
[L01XH01, vorinostat, The risk or severity of QTc prolongation can be increased when Vorinostat is combined with Fluspirilene.]
[A02BX12, bismuth subnitrate, Fluspirilene may increase the neurotoxic activities of Bismuth subnitrate.]
[C07AB07, bisoprolol, The therapeutic efficacy of Fluspirilene can be increased when used in combination with Bisoprolol.]
[J05AG03, efavirenz, The serum concentration of Fluspirilene can be decreased when it is combined with Efavirenz.]
[C07AA17, bopindolol, The risk or severity of bradycardia can be increased when Fluspirilene is combined with Bopindolol.]
[N04AA11, bornaprine, Fluspirilene may increase the central nervous system depressant (CNS depressant) activities of Bornaprine.]
[N05AD06, bromperidol, The risk or severity of adverse effects can be increased when Fluspirilene is combined with Bromperidol.]
[N05CD09, brotizolam, The risk or severity of adverse effects can be increased when Fluspirilene is combined with Brotizolam.]
[C03DA03, canrenone, The risk or severity of hyperkalemia can be increased when Fluspirilene is combined with Canrenone.]
[M01AB07, bumadizone, The risk or severity of hyperkalemia can be increased when Fluspirilene is combined with Bumadizone.]
[N05CA03, butobarbital, The risk or severity of adverse effects can be increased when Butobarbital is combined with Fluspirilene.]
[N06AA15, butriptyline, The risk or severity of QTc prolongation can be increased when Fluspirilene is combined with Butriptyline.]
[C01AA02, acetyldigoxins, Fluspirilene may increase the arrhythmogenic activities of Acetyldigoxin.]
[A10BJ06, semaglutide, The risk or severity of hypoglycemia can be increased when Fluspirilene is combined with Semaglutide.]
[A10BK04, ertugliflozin, The risk or severity of hypoglycemia can be increased when Fluspirilene is combined with Ertugliflozin.]
[N05CA08, butylvinal, The risk or severity of adverse effects can be increased when Fluspirilene is combined with Vinylbital.]
[R06AX18, acrivastine, The risk or severity of QTc prolongation can be increased when Acrivastine is combined with Fluspirilene.]
[C09AA01, captopril, The risk or severity of hyperkalemia can be increased when Captopril is combined with Fluspirilene.]
[V04CD06, macimorelin, The risk or severity of QTc prolongation can be increased when Fluspirilene is combined with Macimorelin.]
[L02BB05, apalutamide, The metabolism of Fluspirilene can be increased when combined with Apalutamide.]
[N03AF01, carbamazepine, The metabolism of Fluspirilene can be increased when combined with Carbamazepine.]
[A06AC08, calcium polycarbophil, The therapeutic efficacy of Calcium polycarbophil can be decreased when used in combination with Fluspirilene.]
[A03AA03, camylofine, Fluspirilene may increase the central nervous system depressant (CNS depressant) activities of Camylofin.]
[R06AA08, carbinoxamine, The risk or severity of QTc prolongation can be increased when Carbinoxamine is combined with Fluspirilene.]
[C07AG02, carvedilol, Carvedilol may increase the arrhythmogenic activities of Fluspirilene.]
[N03AX24, cannabidiol, The risk or severity of adverse effects can be increased when Cannabidiol is combined with Fluspirilene.]
[L01EC03, encorafenib, The risk or severity of QTc prolongation can be increased when Fluspirilene is combined with Encorafenib.]
[C07AB08, celiprolol, Fluspirilene may increase the arrhythmogenic activities of Celiprolol.]
[L01XX62, ivosidenib, The metabolism of Fluspirilene can be increased when combined with Ivosidenib.]
[N03AX17, stiripentol, The metabolism of Fluspirilene can be decreased when combined with Stiripentol.]
[S01GX12, cetirizine, The risk or severity of adverse effects can be increased when Cetirizine is combined with Fluspirilene.]
[N05CM04, carbromal, The risk or severity of adverse effects can be increased when Fluspirilene is combined with Carbromal.]
[A10BB06, carbutamide, The risk or severity of hypoglycemia can be increased when Fluspirilene is combined with Carbutamide.]
[N01BA04, chloroprocaine, The risk or severity of adverse effects can be increased when Chloroprocaine is combined with Fluspirilene.]
[R06AA06, chlorphenoxamine, Fluspirilene may increase the central nervous system depressant (CNS depressant) activities of Chlorphenoxamine.]
[M01AC05, lornoxicam, The risk or severity of hyperkalemia can be increased when Fluspirilene is combined with Lornoxicam.]
[N07XX15, inotersen, The risk or severity of QTc prolongation can be increased when Inotersen is combined with Fluspirilene.]
[M03BA02, carisoprodol, The risk or severity of adverse effects can be increased when Carisoprodol is combined with Fluspirilene.]
[R03BB08, revefenacin, Fluspirilene may increase the central nervous system depressant (CNS depressant) activities of Revefenacin.]
[L01EX13, gilteritinib, The therapeutic efficacy of Fluspirilene can be decreased when used in combination with Gilteritinib.]
[L01XJ03, glasdegib, The risk or severity of QTc prolongation can be increased when Fluspirilene is combined with Glasdegib.]
[N07XX05, amifampridine, The risk or severity of QTc prolongation can be increased when Fluspirilene is combined with Amifampridine.]
[A06AX05, prucalopride, The therapeutic efficacy of Prucalopride can be decreased when used in combination with Fluspirilene.]
[C01BG07, cifenline, Fluspirilene may increase the arrhythmogenic activities of Cibenzoline.]
[C09AA08, cilazapril, The risk or severity of hyperkalemia can be increased when Cilazapril is combined with Fluspirilene.]
[B01AC23, cilostazol, The risk or severity of QTc prolongation can be increased when Cilostazol is combined with Fluspirilene.]
[A03FA08, cinitapride, The risk or severity of adverse effects can be increased when Fluspirilene is combined with Cinitapride.]
[S01ED05, carteolol, Fluspirilene may increase the arrhythmogenic activities of Carteolol.]
[P02BX04, triclabendazole, The risk or severity of QTc prolongation can be increased when Triclabendazole is combined with Fluspirilene.]
[N06AX27, esketamine, The risk or severity of adverse effects can be increased when Fluspirilene is combined with Esketamine.]
[J01FA09, clarithromycin, The metabolism of Fluspirilene can be decreased when combined with Clarithromycin.]
[N06BA14, solriamfetol, The risk or severity of adverse effects can be increased when Fluspirilene is combined with Solriamfetol.]
[N06AX29, brexanolone, The risk or severity of adverse effects can be increased when Fluspirilene is combined with Brexanolone.]
[N05BA09, clobazam, The risk or severity of adverse effects can be increased when Clobazam is combined with Fluspirilene.]
[A06AB05, castor oil, The therapeutic efficacy of Castor oil can be decreased when used in combination with Fluspirilene.]
[N05BA22, cloxazolam, The risk or severity of adverse effects can be increased when Cloxazolam is combined with Fluspirilene.]
[V03AE07, calcium acetate, The therapeutic efficacy of Fluspirilene can be decreased when used in combination with Calcium acetate.]
[C09CA06, candesartan, The risk or severity of hyperkalemia can be increased when Fluspirilene is combined with Candesartan.]
[A12CC06, magnesium lactate, The risk or severity of hypotension can be increased when Magnesium lactate is combined with Fluspirilene.]
[N05AA06, cyamemazine, The risk or severity of adverse effects can be increased when Fluspirilene is combined with Cyamemazine.]
[C03BX03, cicletanine, Fluspirilene may increase the arrhythmogenic activities of Cicletanine.]
[M03BX08, cyclobenzaprine, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Fluspirilene.]
[L01EX14, entrectinib, The risk or severity of QTc prolongation can be increased when Fluspirilene is combined with Entrectinib.]
[N07XX11, pitolisant, The serum concentration of Fluspirilene can be decreased when it is combined with Pitolisant.]
[J01XX12, lefamulin, Lefamulin may increase the QTc-prolonging activities of Fluspirilene.]
[G04BE04, yohimbine, The risk or severity of adverse effects can be increased when Yohimbine is combined with Fluspirilene.]
[A10AE03, insulin, regular, pork, The risk or severity of hypoglycemia can be increased when Fluspirilene is combined with Insulin pork.]
[A06AB03, danthron, The therapeutic efficacy of Dantron can be decreased when used in combination with Fluspirilene.]
[N02CC08, lasmiditan, The risk or severity of serotonin syndrome can be increased when Lasmiditan is combined with Fluspirilene.]
[N03AX25, cenobamate, The serum concentration of Fluspirilene can be decreased when it is combined with Cenobamate.]
[R06AB06, dexbrompheniramine, The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Fluspirilene.]
[R06AB02, dexchlorpheniramine, The risk or severity of QTc prolongation can be increased when Fluspirilene is combined with Dexchlorpheniramine.]
[N02AX03, dezocine, The risk or severity of adverse effects can be increased when Dezocine is combined with Fluspirilene.]
[N05CM21, lemborexant, The risk or severity of adverse effects can be increased when Fluspirilene is combined with Lemborexant.]
[N05AD10, lumateperone, The risk or severity of adverse effects can be increased when Lumateperone is combined with Fluspirilene.]
[S01AE06, gatifloxacin, The risk or severity of QTc prolongation can be increased when Gatifloxacin is combined with Fluspirilene.]
[J05AE05, amprenavir, The metabolism of Fluspirilene can be decreased when combined with Amprenavir.]
[N02CC07, frovatriptan, The risk or severity of adverse effects can be increased when Frovatriptan is combined with Fluspirilene.]
[N05CC04, dichloralphenazone, The risk or severity of adverse effects can be increased when Dichloralphenazone is combined with Fluspirilene.]
[A07DA04, difenoxin, The risk or severity of adverse effects can be increased when Difenoxin is combined with Fluspirilene.]
[N02AA08, dihydrocodeine, The risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Fluspirilene.]
[N02CC06, eletriptan, The risk or severity of adverse effects can be increased when Eletriptan is combined with Fluspirilene.]
[M01AH02, rofecoxib, The risk or severity of hyperkalemia can be increased when Rofecoxib is combined with Fluspirilene.]
[C08CA16, clevidipine, Fluspirilene may increase the arrhythmogenic activities of Clevidipine.]
[C01BD07, dronedarone, Fluspirilene may increase the arrhythmogenic activities of Dronedarone.]
[N03AG02, dipropylacetamide, The risk or severity of adverse effects can be increased when Valpromide is combined with Fluspirilene.]
[R06AE04, chlorcyclizine, The risk or severity of QTc prolongation can be increased when Chlorcyclizine is combined with Fluspirilene.]
[N05BA02, chlordiazepoxide, The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Fluspirilene.]
[L01EH03, tucatinib, The metabolism of Tucatinib can be decreased when combined with Fluspirilene.]
[A03AA08, dihexyverine, Fluspirilene may increase the central nervous system depressant (CNS depressant) activities of Dihexyverine.]
[C01CA14, dopexamine, The therapeutic efficacy of Dopexamine can be decreased when used in combination with Fluspirilene.]
[G04BD09, trospium, Fluspirilene may increase the central nervous system depressant (CNS depressant) activities of Trospium.]
[M01AC04, droxicam, The risk or severity of hyperkalemia can be increased when Fluspirilene is combined with Droxicam.]
[M02AA27, dexketoprofen, The risk or severity of hyperkalemia can be increased when Fluspirilene is combined with Dexketoprofen.]
[N05CM02, chlormethiazole, The risk or severity of adverse effects can be increased when Fluspirilene is combined with Clomethiazole.]
[M03BB02, chlormezanone, The risk or severity of adverse effects can be increased when Chlormezanone is combined with Fluspirilene.]
[R02AD04, dyclonine, The risk or severity of adverse effects can be increased when Dyclonine is combined with Fluspirilene.]
[R06AX22, ebastine, The risk or severity of QTc prolongation can be increased when Ebastine is combined with Fluspirilene.]
[J05AX29, fostemsavir, The risk or severity of QTc prolongation can be increased when Fostemsavir is combined with Fluspirilene.]
[N05CD14, remimazolam, The risk or severity of adverse effects can be increased when Fluspirilene is combined with Remimazolam.]
[L04AC19, satralizumab, The serum concentration of Fluspirilene can be decreased when it is combined with Satralizumab.]
[N02AX07, oliceridine, The risk or severity of hypotension, sedation, death, somnolence, and respiratory depression can be increased when Fluspirilene is combined with Oliceridine.]
[P01BA01, chloroquine, The risk or severity of QTc prolongation can be increased when Chloroquine is combined with Fluspirilene.]
[R06AB04, chlorpheniramine, The risk or severity of adverse effects can be increased when Chlorpheniramine is combined with Fluspirilene.]
[N05AA01, chlorpromazine, Fluspirilene may increase the central nervous system depressant (CNS depressant) activities of Chlorpromazine.]
[A10BB02, chlorpropamide, The risk or severity of hypoglycemia can be increased when Fluspirilene is combined with Chlorpropamide.]
[N05AF03, chlorprothixene, Fluspirilene may increase the central nervous system depressant (CNS depressant) activities of Chlorprothixene.]
[M03BB03, chlorzoxazone, The risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Fluspirilene.]
[N05BX03, etifoxine, The risk or severity of adverse effects can be increased when Fluspirilene is combined with Etifoxine.]
[N02BA07, ethenzamide, The risk or severity of hyperkalemia can be increased when Fluspirilene is combined with Ethenzamide.]
[N06BX18, vinpocetine, Fluspirilene may increase the arrhythmogenic activities of Vinpocetine.]
[N05BA18, ethyl loflazepate, The risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Fluspirilene.]
[M01AB08, etodolac, The risk or severity of hyperkalemia can be increased when Etodolac is combined with Fluspirilene.]
[M02AA06, etofenamate, The risk or severity of hyperkalemia can be increased when Fluspirilene is combined with Etofenamate.]
[B06AC06, berotralstat, The risk or severity of QTc prolongation can be increased when Fluspirilene is combined with Berotralstat.]
[A16AX20, lonafarnib, The metabolism of Fluspirilene can be decreased when combined with Lonafarnib.]
[M09AA01, hydroquinine, Fluspirilene may increase the arrhythmogenic activities of Hydroquinine.]
[L02BX04, relugolix, The risk or severity of QTc prolongation can be increased when Relugolix is combined with Fluspirilene.]
[L01FX21, naxitamab, Fluspirilene may increase the neurotoxic activities of Naxitamab.]
[P03AX07, abametapir, The serum concentration of Fluspirilene can be increased when it is combined with Abametapir.]
[M03BA05, febarbamate, The risk or severity of adverse effects can be increased when Fluspirilene is combined with Febarbamate.]
[N03AX10, felbamate, The risk or severity of adverse effects can be increased when Felbamate is combined with Fluspirilene.]
[M01AE05, fenbufen, The risk or severity of hyperkalemia can be increased when Fluspirilene is combined with Fenbufen.]
[C01CA19, fenoldopam, The therapeutic efficacy of Fenoldopam can be decreased when used in combination with Fluspirilene.]
[J01MB07, flumequine, The risk or severity of QTc prolongation can be increased when Flumequine is combined with Fluspirilene.]
[R03CC15, formoterol, The risk or severity of QTc prolongation can be increased when Formoterol is combined with Fluspirilene.]
[A10AF01, insulin, regular, human, The risk or severity of hypoglycemia can be increased when Fluspirilene is combined with Insulin human.]
[L04AA50, ponesimod, The risk or severity of bradycardia can be increased when Ponesimod is combined with Fluspirilene.]
[N01AB05, trichloroethylene, The risk or severity of adverse effects can be increased when Fluspirilene is combined with Trichloroethylene.]
[A02BA01, cimetidine, The serum concentration of Fluspirilene can be increased when it is combined with Cimetidine.]
[N02BF01, gabapentin, The risk or severity of adverse effects can be increased when Gabapentin is combined with Fluspirilene.]
[N07CA02, cinnarizine, Cinnarizine may increase the arrhythmogenic activities of Fluspirilene.]
[J01MB06, cinoxacin, The risk or severity of QTc prolongation can be increased when Cinoxacin is combined with Fluspirilene.]
[L01XX73, sotorasib, The serum concentration of Fluspirilene can be decreased when it is combined with Sotorasib.]
[S03AA07, ciprofloxacin, The risk or severity of QTc prolongation can be increased when Ciprofloxacin is combined with Fluspirilene.]
[N06AB04, citalopram, The risk or severity of QTc prolongation can be increased when Fluspirilene is combined with Citalopram.]
[C03DA05, finerenone, The risk or severity of hyperkalemia can be increased when Fluspirilene is combined with Finerenone.]
[P01CA03, fexinidazole, The risk or severity of adverse effects can be increased when Fluspirilene is combined with Fexinidazole.]
[L01EB10, mobocertinib, The risk or severity of QTc prolongation can be increased when Fluspirilene is combined with Mobocertinib.]
[R06AA04, clemastine, The risk or severity of QTc prolongation can be increased when Fluspirilene is combined with Clemastine.]
[A10BB12, glimepiride, The risk or severity of hypoglycemia can be increased when Fluspirilene is combined with Glimepiride.]
[A10BB08, gliquidone, The risk or severity of hypoglycemia can be increased when Fluspirilene is combined with Gliquidone.]
[A12AA02, calcium glubionate, The therapeutic efficacy of Fluspirilene can be decreased when used in combination with Calcium glubionate anhydrous.]
[J01FF01, clindamycin, Clindamycin may increase the neurotoxic activities of Fluspirilene.]
[N06AX25, St. John's wort extract, The metabolism of Fluspirilene can be increased when combined with St. John's Wort.]
[L03AB15, ropeginterferon alfa-2b, The risk or severity of neuropsychiatric effects can be increased when Ropeginterferon alfa-2b is combined with Fluspirilene.]
[J04BA01, clofazimine, The risk or severity of QTc prolongation can be increased when Clofazimine is combined with Fluspirilene.]
[N01BB10, levobupivacaine, The risk or severity of adverse effects can be increased when Levobupivacaine is combined with Fluspirilene.]
[L01EJ03, pacritinib, The risk or severity of QTc prolongation can be increased when Pacritinib is combined with Fluspirilene.]
[N06AA04, clomipramine, The risk or severity of adverse effects can be increased when Clomipramine is combined with Fluspirilene.]
[N03AE01, clonazepam, The risk or severity of adverse effects can be increased when Clonazepam is combined with Fluspirilene.]
[S01EA04, clonidine, The risk or severity of sedation can be increased when Clonidine is combined with Fluspirilene.]
[C01EB24, mavacamten, The serum concentration of Fluspirilene can be decreased when it is combined with Mavacamten.]
[A10BX16, tirzepatide, The risk or severity of hypoglycemia can be increased when Fluspirilene is combined with Tirzepatide.]
[J02AC06, oteseconazole, The therapeutic efficacy of Oteseconazole can be increased when used in combination with Fluspirilene.]
[N05AH06, clothiapine, The risk or severity of adverse effects can be increased when Fluspirilene is combined with Clothiapine.]
[N05BA21, clotiazepam, The risk or severity of adverse effects can be increased when Clotiazepam is combined with Fluspirilene.]
[A04AA01, ondansetron, The risk or severity of QTc prolongation can be increased when Ondansetron is combined with Fluspirilene.]
[A04AA02, granisetron, The risk or severity of QTc prolongation can be increased when Granisetron is combined with Fluspirilene.]
[N05AH02, clozapine, Fluspirilene may increase the central nervous system depressant (CNS depressant) activities of Clozapine.]
[A10BX01, guar gum, The risk or severity of hypoglycemia can be increased when Fluspirilene is combined with Guar gum.]
[A10BK06, sotagliflozin, The risk or severity of hypoglycemia can be increased when Fluspirilene is combined with Sotagliflozin.]
[N05BA13, halazepam, The risk or severity of adverse effects can be increased when Halazepam is combined with Fluspirilene.]
[H01AC08, somatrogon, The metabolism of Fluspirilene can be increased when combined with Somatrogon.]
[S02DA02, cocaine, The risk or severity of QTc prolongation can be increased when Fluspirilene is combined with Cocaine.]
[C02KB01, metyrosine, Fluspirilene may increase the sedative activities of Metyrosine.]
[M01AX13, proquazone, The risk or severity of hyperkalemia can be increased when Fluspirilene is combined with Proquazone.]
[R05DA04, codeine, The risk or severity of adverse effects can be increased when Codeine is combined with Fluspirilene.]
[M03AC05, hexafluorenium, The risk or severity of adverse effects can be increased when Hexafluronium is combined with Fluspirilene.]
[A03AB10, hexocyclium, Fluspirilene may increase the central nervous system depressant (CNS depressant) activities of Hexocyclium.]
[A03BB06, homatropine methylbromide, Fluspirilene may increase the central nervous system depressant (CNS depressant) activities of Homatropine methylbromide.]
[C01BA13, hydroquinidine, Fluspirilene may increase the arrhythmogenic activities of Hydroquinidine.]
[A02AD04, hydrotalcite, The risk or severity of hypotension can be increased when Hydrotalcite is combined with Fluspirilene.]
[N01AB07, desflurane, The risk or severity of adverse effects can be increased when Desflurane is combined with Fluspirilene.]
[A04AA03, tropisetron, Fluspirilene may increase the arrhythmogenic activities of Tropisetron.]
[C04AX28, ifenprodil, The risk or severity of adverse effects can be increased when Fluspirilene is combined with Ifenprodil.]
[A10BX03, nateglinide, The risk or severity of hypoglycemia can be increased when Fluspirilene is combined with Nateglinide.]
[N02BA16, imidazole-2-hydroxybenzoate, The risk or severity of hyperkalemia can be increased when Fluspirilene is combined with Imidazole salicylate.]
[H01AC03, mecasermin, The risk or severity of hypoglycemia can be increased when Fluspirilene is combined with Mecasermin.]
[A10AE04, insulin glargine, The risk or severity of hypoglycemia can be increased when Fluspirilene is combined with Insulin glargine.]
[J01FA15, telithromycin, The metabolism of Fluspirilene can be decreased when combined with Telithromycin.]
[B01AC10, indobufen, The risk or severity of hyperkalemia can be increased when Fluspirilene is combined with Indobufen.]
[R06AX27, desloratadine, The risk or severity of QTc prolongation can be increased when Desloratadine is combined with Fluspirilene.]
[M01AH03, valdecoxib, The risk or severity of hyperkalemia can be increased when Valdecoxib is combined with Fluspirilene.]
[C01AA06, lanatoside C, The serum concentration of Lanatoside C can be increased when it is combined with Fluspirilene.]
[N02CC05, almotriptan, The risk or severity of adverse effects can be increased when Almotriptan is combined with Fluspirilene.]
[M01AH04, parecoxib, The risk or severity of hyperkalemia can be increased when Fluspirilene is combined with Parecoxib.]
[J02AC02, itraconazole, The metabolism of Fluspirilene can be decreased when combined with Itraconazole.]
[B01AB12, bemiparin, The risk or severity of hyperkalemia can be increased when Fluspirilene is combined with Bemiparin.]
[S01GX06, emedastine, The risk or severity of QTc prolongation can be increased when Emedastine is combined with Fluspirilene.]
[N05BA10, ketazolam, The risk or severity of adverse effects can be increased when Ketazolam is combined with Fluspirilene.]
[M01AA06, kebuzone, The risk or severity of hyperkalemia can be increased when Fluspirilene is combined with Kebuzone.]
[L01EA01, imatinib, The risk or severity of QTc prolongation can be increased when Fluspirilene is combined with Imatinib.]
[J02AC04, posaconazole, The metabolism of Fluspirilene can be decreased when combined with Posaconazole.]
[C08CA09, lacidipine, Fluspirilene may increase the arrhythmogenic activities of Lacidipine.]
[A06AD12, lactitol, The therapeutic efficacy of Lactitol can be decreased when used in combination with Fluspirilene.]
[N03AX09, lamotrigine, Lamotrigine may increase the arrhythmogenic activities of Fluspirilene.]
[S01GX02, levocabastine, The risk or severity of QTc prolongation can be increased when Levocabastine is combined with Fluspirilene.]
[N07BC04, lofexidine, The therapeutic efficacy of Fluspirilene can be increased when used in combination with Lofexidine.]
[S01AE04, lomefloxacin, The risk or severity of QTc prolongation can be increased when Lomefloxacin is combined with Fluspirilene.]
[M01AB09, lonazolac, The risk or severity of hyperkalemia can be increased when Fluspirilene is combined with Lonazolac.]
[N05CD06, lormetazepam, The risk or severity of adverse effects can be increased when Fluspirilene is combined with Lormetazepam.]
[M02AA31, loxoprofen, The risk or severity of hyperkalemia can be increased when Fluspirilene is combined with Loxoprofen.]
[C09AA03, lisinopril, The risk or severity of hyperkalemia can be increased when Lisinopril is combined with Fluspirilene.]
[A02AD02, magaldrate, The risk or severity of hypotension can be increased when Magaldrate is combined with Fluspirilene.]
[A06AD01, magnesium carbonate, The risk or severity of hypotension can be increased when Magnesium carbonate is combined with Fluspirilene.]
[C08CA11, manidipine, Fluspirilene may increase the arrhythmogenic activities of Manidipine.]
[A03AA04, mebeverine, Fluspirilene may increase the central nervous system depressant (CNS depressant) activities of Mebeverine.]
[N06AX13, medifoxamine, The risk or severity of adverse effects can be increased when Fluspirilene is combined with Medifoxamine.]
[C07AA14, mepindolol, The risk or severity of bradycardia can be increased when Fluspirilene is combined with Mepindolol.]
[R06AD07, mequitazine, Fluspirilene may increase the arrhythmogenic activities of Mequitazine.]
[C01EB10, adenosine, Adenosine may increase the arrhythmogenic activities of Fluspirilene.]
[N04AA03, methixene, Fluspirilene may increase the central nervous system depressant (CNS depressant) activities of Metixene.]
[C04AX01, cyclandelate, Cyclandelate may increase the arrhythmogenic activities of Fluspirilene.]
[R03CB02, methoxyphenamine, Fluspirilene may decrease the stimulatory activities of Methoxyphenamine.]
[R06AE03, cyclizine, The risk or severity of adverse effects can be increased when Cyclizine is combined with Fluspirilene.]
[N05CA10, cyclobarbital, The risk or severity of adverse effects can be increased when Fluspirilene is combined with Cyclobarbital.]
[C03DA04, eplerenone, The risk or severity of hyperkalemia can be increased when Eplerenone is combined with Fluspirilene.]
[N05AD03, metylperon, Fluspirilene may increase the arrhythmogenic activities of Melperone.]
[A10BF02, miglitol, The risk or severity of hypoglycemia can be increased when Fluspirilene is combined with Miglitol.]
[L01AA01, cyclophosphamide, Cyclophosphamide may increase the neurotoxic activities of Fluspirilene.]
[N06AX07, minaprine, The risk or severity of adverse effects can be increased when Minaprine is combined with Fluspirilene.]
[J04AB01, cycloserine, Cycloserine may increase the neurotoxic activities of Fluspirilene.]
[S01XA18, cyclosporine, The metabolism of Fluspirilene can be decreased when combined with Cyclosporine.]
[N06AG02, moclobemide, The risk or severity of adverse effects can be increased when Moclobemide is combined with Fluspirilene.]
[R06AX02, cyproheptadine, Fluspirilene may increase the central nervous system depressant (CNS depressant) activities of Cyproheptadine.]
[C09AA13, moexipril, The risk or severity of QTc prolongation can be increased when Moexipril is combined with Fluspirilene.]
[M02AA02, mofebutazone, The risk or severity of hyperkalemia can be increased when Fluspirilene is combined with Mofebutazone.]
[M01AX22, morniflumate, The risk or severity of hyperkalemia can be increased when Fluspirilene is combined with Morniflumate.]
[C03XA02, conivaptan, The metabolism of Fluspirilene can be decreased when combined with Conivaptan.]
[G04BE09, vardenafil, The risk or severity of QTc prolongation can be increased when Vardenafil is combined with Fluspirilene.]
[M01AH05, etoricoxib, The risk or severity of hyperkalemia can be increased when Etoricoxib is combined with Fluspirilene.]
[G03XA01, danazol, The metabolism of Fluspirilene can be decreased when combined with Danazol.]
[M03CA01, dantrolene, The risk or severity of hyperkalemia can be increased when Dantrolene is combined with Fluspirilene.]
[N06BX04, deanol, The risk or severity of adverse effects can be increased when Fluspirilene is combined with Deanol.]
[A04AD11, nabilone, Nabilone may increase the central nervous system depressant (CNS depressant) activities of Fluspirilene.]
[M01AX01, nabumetone, The risk or severity of hyperkalemia can be increased when Nabumetone is combined with Fluspirilene.]
[B05XA15, potassium lactate, Potassium lactate may increase the hyperkalemic activities of Fluspirilene.]
[N05BA16, nordazepam, The risk or severity of adverse effects can be increased when Fluspirilene is combined with Nordazepam.]
[C07AB12, nebivolol, Fluspirilene may increase the arrhythmogenic activities of Nebivolol.]
[N06AX06, nefazodone, The metabolism of Fluspirilene can be decreased when combined with Nefazodone.]
[N05CM16, niaprazine, The risk or severity of adverse effects can be increased when Fluspirilene is combined with Niaprazine.]
[C01DX16, nicorandil, Fluspirilene may increase the arrhythmogenic activities of Nicorandil.]
[N03AG06, tiagabine, The risk or severity of adverse effects can be increased when Tiagabine is combined with Fluspirilene.]
[M03AC11, cisatracurium, Fluspirilene may increase the neuromuscular blocking activities of Cisatracurium.]
[R05DA06, normethadone, The risk or severity of adverse effects can be increased when Fluspirilene is combined with Normethadone.]
[N06AB10, escitalopram, The risk or severity of serotonin syndrome can be increased when Fluspirilene is combined with Escitalopram.]
[G04BD08, solifenacin, Fluspirilene may increase the central nervous system depressant (CNS depressant) activities of Solifenacin.]
[A07EC03, olsalazine, The risk or severity of hyperkalemia can be increased when Olsalazine is combined with Fluspirilene.]
[N06AA01, desipramine, Fluspirilene may increase the central nervous system depressant (CNS depressant) activities of Desipramine.]
[C01AA07, deslanoside, Deslanoside may increase the arrhythmogenic activities of Fluspirilene.]
[C09XA02, aliskiren, The risk or severity of hyperkalemia can be increased when Fluspirilene is combined with Aliskiren.]
[L01XA03, oxaliplatin, The risk or severity of QTc prolongation can be increased when Oxaliplatin is combined with Fluspirilene.]
[M01AE12, oxaprozin, The risk or severity of hyperkalemia can be increased when Oxaprozin is combined with Fluspirilene.]
[N03AF02, oxcarbazepine, The risk or severity of adverse effects can be increased when Oxcarbazepine is combined with Fluspirilene.]
[S03BA01, dexamethasone, The metabolism of Fluspirilene can be increased when combined with Dexamethasone.]
[N06BX07, oxiracetam, The risk or severity of adverse effects can be increased when Fluspirilene is combined with Oxiracetam.]
[N04AA08, dexetimide, Fluspirilene may increase the central nervous system depressant (CNS depressant) activities of Dexetimide.]
[G04BD04, oxybutynin, Fluspirilene may increase the central nervous system depressant (CNS depressant) activities of Oxybutynin.]
[A08AA04, dexfenfluramine, The risk or severity of serotonin syndrome can be increased when Dexfenfluramine is combined with Fluspirilene.]
[A03AA01, oxyphencyclimine, Fluspirilene may increase the central nervous system depressant (CNS depressant) activities of Oxyphencyclimine.]
[N06BA02, dextroamphetamine, Fluspirilene may decrease the stimulatory activities of Amphetamine.]
[R05DA09, dextromethorphan, The risk or severity of adverse effects can be increased when Dextromethorphan is combined with Fluspirilene.]
[N03AC01, paramethadione, The risk or severity of adverse effects can be increased when Paramethadione is combined with Fluspirilene.]
[N02AC01, dextromoramide, The risk or severity of adverse effects can be increased when Dextromoramide is combined with Fluspirilene.]
[N06AB05, paroxetine, The risk or severity of adverse effects can be increased when Fluspirilene is combined with Paroxetine.]
[B01AC04, clopidogrel, The therapeutic efficacy of Clopidogrel can be decreased when used in combination with Fluspirilene.]
[N07BC06, heroin, The risk or severity of adverse effects can be increased when Diamorphine is combined with Fluspirilene.]
[N05BA01, diazepam, The risk or severity of adverse effects can be increased when Diazepam is combined with Fluspirilene.]
[N03AX07, phenacemide, The risk or severity of adverse effects can be increased when Phenacemide is combined with Fluspirilene.]
[N03AD02, phensuximide, The risk or severity of adverse effects can be increased when Phensuximide is combined with Fluspirilene.]
[N06AA08, dibenzepin, The risk or severity of adverse effects can be increased when Fluspirilene is combined with Dibenzepin.]
[S02DA04, dibucaine, The risk or severity of adverse effects can be increased when Cinchocaine is combined with Fluspirilene.]
[S01BC03, diclofenac, The risk or severity of hyperkalemia can be increased when Diclofenac is combined with Fluspirilene.]
[J05AD01, foscarnet, The risk or severity of QTc prolongation can be increased when Foscarnet is combined with Fluspirilene.]
[A03AA07, dicyclomine, Fluspirilene may increase the central nervous system depressant (CNS depressant) activities of Dicyclomine.]
[J05AF02, didanosine, Didanosine may increase the neurotoxic activities of Fluspirilene.]
[A03AX04, pinaverium, Fluspirilene may increase the arrhythmogenic activities of Pinaverium.]
[A10BG03, pioglitazone, The risk or severity of hypoglycemia can be increased when Fluspirilene is combined with Pioglitazone.]
[N05AD05, pipamperone, The risk or severity of adverse effects can be increased when Fluspirilene is combined with Pipamperone.]
[A03AB14, pipenzolate, Fluspirilene may increase the central nervous system depressant (CNS depressant) activities of Pipenzolate.]
[L01EB02, erlotinib, The risk or severity of QTc prolongation can be increased when Fluspirilene is combined with Erlotinib.]
[A08AA03, diethylpropion, Fluspirilene may decrease the stimulatory activities of Diethylpropion.]
[C08CA03, isradipine, Isradipine may increase the arrhythmogenic activities of Fluspirilene.]
[A03AB11, poldine, Fluspirilene may increase the central nervous system depressant (CNS depressant) activities of Poldine.]
[N02BA11, diflunisal, The risk or severity of hyperkalemia can be increased when Diflunisal is combined with Fluspirilene.]
[C01AA04, digitoxin, Digitoxin may increase the arrhythmogenic activities of Fluspirilene.]
[C01AA05, digoxin, Digoxin may increase the arrhythmogenic activities of Fluspirilene.]
[N02CA01, dihydroergotamine, The risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Fluspirilene.]
[N02AA03, hydromorphone, The risk or severity of adverse effects can be increased when Hydromorphone is combined with Fluspirilene.]
[J05AE08, atazanavir, The metabolism of Fluspirilene can be decreased when combined with Atazanavir.]
[B01AC21, treprostinil, The risk or severity of QTc prolongation can be increased when Treprostinil is combined with Fluspirilene.]
[H03BC01, potassium perchlorate, Potassium perchlorate may increase the hyperkalemic activities of Fluspirilene.]
[D04AB07, pramoxine, The risk or severity of adverse effects can be increased when Fluspirilene is combined with Pramocaine.]
[C08DB01, diltiazem, Diltiazem may increase the arrhythmogenic activities of Fluspirilene.]
[R06AA11, dimenhydrinate, The risk or severity of QTc prolongation can be increased when Dimenhydrinate is combined with Fluspirilene.]
[M03BX03, pridinol, The risk or severity of adverse effects can be increased when Fluspirilene is combined with Pridinol.]
[R06AB03, dimethindene, Fluspirilene may increase the central nervous system depressant (CNS depressant) activities of Dimetindene.]
[N03AG05, progabide, The risk or severity of adverse effects can be increased when Progabide is combined with Fluspirilene.]
[N02BB04, propyphenazone, The risk or severity of hyperkalemia can be increased when Fluspirilene is combined with Propyphenazone.]
[M01AB14, proglumetacin, The risk or severity of hyperkalemia can be increased when Fluspirilene is combined with Proglumetacin.]
[R06AA02, diphenhydramine, Fluspirilene may increase the central nervous system depressant (CNS depressant) activities of Diphenhydramine.]
[A07DA01, diphenoxylate, The risk or severity of adverse effects can be increased when Diphenoxylate is combined with Fluspirilene.]
[N05CD10, quazepam, The risk or severity of adverse effects can be increased when Quazepam is combined with Fluspirilene.]
[C09AA06, quinapril, The risk or severity of hyperkalemia can be increased when Quinapril is combined with Fluspirilene.]
[N06BA11, dexmethylphenidate, The risk or severity of adverse effects can be increased when Fluspirilene is combined with Dexmethylphenidate.]
[N06AA23, quinupramine, The risk or severity of adverse effects can be increased when Fluspirilene is combined with Quinupramine.]
[A03FA02, cisapride, The risk or severity of QTc prolongation can be increased when Fluspirilene is combined with Cisapride.]
[C09AA05, ramipril, The risk or severity of hyperkalemia can be increased when Ramipril is combined with Fluspirilene.]
[S01XA23, sirolimus, Fluspirilene may increase the immunosuppressive activities of Sirolimus.]
[N05AL04, remoxipride, The risk or severity of adverse effects can be increased when Remoxipride is combined with Fluspirilene.]
[C01BA03, disopyramide, Disopyramide may increase the arrhythmogenic activities of Fluspirilene.]
[P03AA04, disulfiram, The risk or severity of QTc prolongation can be increased when Disulfiram is combined with Fluspirilene.]
[S02AA12, rifamycin SV, The metabolism of Fluspirilene can be increased when combined with Rifamycin.]
[J04AB05, rifapentine, The metabolism of Fluspirilene can be increased when combined with Rifapentine.]
[N07XX02, riluzole, The risk or severity of adverse effects can be increased when Riluzole is combined with Fluspirilene.]
[N05AX08, risperidone, The risk or severity of hypotension can be increased when Risperidone is combined with Fluspirilene.]
[R06AE09, levocetirizine, The risk or severity of adverse effects can be increased when Fluspirilene is combined with Levocetirizine.]
[N01BB09, ropivacaine, The risk or severity of adverse effects can be increased when Ropivacaine is combined with Fluspirilene.]
[J01MB01, rosoxacin, The risk or severity of QTc prolongation can be increased when Rosoxacin is combined with Fluspirilene.]
[L01EX01, sunitinib, The risk or severity of hypoglycemia can be increased when Fluspirilene is combined with Sunitinib.]
[A04AD12, aprepitant, The metabolism of Fluspirilene can be decreased when combined with Aprepitant.]
[C03XA01, tolvaptan, The risk or severity of hyperkalemia can be increased when Fluspirilene is combined with Tolvaptan.]
[L01XG01, bortezomib, The risk or severity of QTc prolongation can be increased when Bortezomib is combined with Fluspirilene.]
[S01BC05, ketorolac, The risk or severity of hyperkalemia can be increased when Ketorolac is combined with Fluspirilene.]
[C01EB18, ranolazine, The risk or severity of QTc prolongation can be increased when Ranolazine is combined with Fluspirilene.]
[N02BA06, salsalate, The risk or severity of hyperkalemia can be increased when Salsalate is combined with Fluspirilene.]
[R03AC12, salmeterol, The risk or severity of QTc prolongation can be increased when Salmeterol is combined with Fluspirilene.]
[A03FA03, domperidone, The risk or severity of QTc prolongation can be increased when Fluspirilene is combined with Domperidone.]
[N06AA16, dothiepin, Fluspirilene may increase the central nervous system depressant (CNS depressant) activities of Dosulepin.]
[N06AA12, doxepin, Fluspirilene may increase the central nervous system depressant (CNS depressant) activities of Doxepin.]
[A06AB06, sennosides, USP, The therapeutic efficacy of Sennosides can be decreased when used in combination with Fluspirilene.]
[R06AA09, doxylamine, Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Fluspirilene.]
[N06AB06, sertraline, The risk or severity of adverse effects can be increased when Fluspirilene is combined with Sertraline.]
[N01AB08, sevoflurane, The risk or severity of hypotension can be increased when Sevoflurane is combined with Fluspirilene.]
[N05AD08, droperidol, Droperidol may increase the central nervous system depressant (CNS depressant) activities of Fluspirilene.]
[A08AA10, sibutramine, The risk or severity of adverse effects can be increased when Fluspirilene is combined with Sibutramine.]
[V03AG05, sodium phosphate, Sodium phosphate, monobasic may increase the hyperkalemic activities of Fluspirilene.]
[A12CA02, sodium sulfate, The therapeutic efficacy of Sodium sulfate can be decreased when used in combination with Fluspirilene.]
[C09AA11, spirapril, The risk or severity of hyperkalemia can be increased when Spirapril is combined with Fluspirilene.]
[N05AL02, sultopride, The risk or severity of QTc prolongation can be increased when Fluspirilene is combined with Sultopride.]
[N02CC01, sumatriptan, The risk or severity of adverse effects can be increased when Sumatriptan is combined with Fluspirilene.]
[C07AB13, talinolol, Fluspirilene may increase the arrhythmogenic activities of Talinolol.]
[J01MA05, temafloxacin, The risk or severity of QTc prolongation can be increased when Fluspirilene is combined with Temafloxacin.]
[M01AC02, tenoxicam, The risk or severity of hyperkalemia can be increased when Tenoxicam is combined with Fluspirilene.]
[G04CA03, terazosin, The risk or severity of hypotension can be increased when Terazosin is combined with Fluspirilene.]
[G04BD05, terodiline, Fluspirilene may increase the arrhythmogenic activities of Terodiline.]
[C07AA16, tertatolol, Fluspirilene may increase the arrhythmogenic activities of Tertatolol.]
[M03BX07, tetrazepam, The risk or severity of adverse effects can be increased when Fluspirilene is combined with Tetrazepam.]
[M03BX05, thiocolchicoside, The risk or severity of adverse effects can be increased when Fluspirilene is combined with Thiocolchicoside.]
[N05AB05, thiopropazate, The risk or severity of adverse effects can be increased when Fluspirilene is combined with Thiopropazate.]
[G04BD01, emepronium, Fluspirilene may increase the central nervous system depressant (CNS depressant) activities of Emepronium.]
[N06AX14, tianeptine, The risk or severity of adverse effects can be increased when Tianeptine is combined with Fluspirilene.]
[C09AA02, enalapril, The risk or severity of hyperkalemia can be increased when Enalapril is combined with Fluspirilene.]
[N05BA23, tofisopam, The risk or severity of adverse effects can be increased when Fluspirilene is combined with Tofisopam.]
[M01AG02, tolfenamic acid, Fluspirilene may increase the bradycardic activities of Tolfenamic acid.]
[N06AG03, toloxatone, The risk or severity of adverse effects can be increased when Fluspirilene is combined with Toloxatone.]
[N06BA09, atomoxetine, The risk or severity of QTc prolongation can be increased when Atomoxetine is combined with Fluspirilene.]
[N03AX11, topiramate, The risk or severity of adverse effects can be increased when Topiramate is combined with Fluspirilene.]
[L02BA02, toremifene, The risk or severity of QTc prolongation can be increased when Fluspirilene is combined with Toremifene.]
[C09AA10, trandolapril, The risk or severity of hyperkalemia can be increased when Trandolapril is combined with Fluspirilene.]
[N05CD11, triazulenone, The risk or severity of adverse effects can be increased when Fluspirilene is combined with Loprazolam.]
[N05CC01, chloral hydrate, The risk or severity of adverse effects can be increased when Chloral hydrate is combined with Fluspirilene.]
[N05CM07, triclofos, The risk or severity of adverse effects can be increased when Fluspirilene is combined with Triclofos.]
[A03AB08, tridihexethyl, Fluspirilene may increase the central nervous system depressant (CNS depressant) activities of Tridihexethyl.]
[R06AA10, trimethobenzamide, The risk or severity of adverse effects can be increased when Trimethobenzamide is combined with Fluspirilene.]
[L02AE04, triptorelin, The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Fluspirilene.]
[N04AA12, tropatepine, Fluspirilene may increase the central nervous system depressant (CNS depressant) activities of Tropatepine.]
[N01AB04, enflurane, The risk or severity of adverse effects can be increased when Enflurane is combined with Fluspirilene.]
[C02CA06, urapidil, The risk or severity of hypotension can be increased when Urapidil is combined with Fluspirilene.]
[J01MA04, enoxacin, The risk or severity of QTc prolongation can be increased when Enoxacin is combined with Fluspirilene.]
[N05AL06, veralipride, The risk or severity of adverse effects can be increased when Fluspirilene is combined with Veralipride.]
[L01CA04, vinorelbine, Vinorelbine may increase the neurotoxic activities of Fluspirilene.]
[S01GX10, epinastine, The risk or severity of adverse effects can be increased when Epinastine is combined with Fluspirilene.]
[N06AX16, venlafaxine, The risk or severity of serotonin syndrome can be increased when Fluspirilene is combined with Venlafaxine.]
[S01GA03, xylometazoline, Fluspirilene may increase the arrhythmogenic activities of Xylometazoline.]
[C08CA12, mepirodipine, Fluspirilene may increase the arrhythmogenic activities of Barnidipine.]
[C09AA15, zofenopril, The risk or severity of hyperkalemia can be increased when Fluspirilene is combined with Zofenopril.]
[N05CF02, zolpidem, Fluspirilene may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.]
[M01AB04, zomepirac, The risk or severity of hyperkalemia can be increased when Zomepirac is combined with Fluspirilene.]
[N03AX15, zonisamide, Zonisamide may increase the arrhythmogenic activities of Fluspirilene.]
[A10AB06, insulin glulisine, human, The risk or severity of hypoglycemia can be increased when Fluspirilene is combined with Insulin glulisine.]
[N05CF01, zopiclone, The risk or severity of adverse effects can be increased when Fluspirilene is combined with Zopiclone.]
[N05AX11, zotepine, The risk or severity of adverse effects can be increased when Fluspirilene is combined with Zotepine.]
[C02AC02, guanfacine, The risk or severity of adverse effects can be increased when Guanfacine is combined with Fluspirilene.]
[C01BG01, moricizine, Moricizine may increase the arrhythmogenic activities of Fluspirilene.]
[G02AB03, ergonovine, The risk or severity of adverse effects can be increased when Ergometrine is combined with Fluspirilene.]
[C04AE01, ergoloid mesylates, USP, The risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Fluspirilene.]
[N02CA02, ergotamine, The metabolism of Fluspirilene can be decreased when combined with Ergotamine.]
[N03AG01, valproic acid, The risk or severity of QTc prolongation can be increased when Fluspirilene is combined with Valproic acid.]
[C01DA13, erythrityl tetranitrate, Fluspirilene may increase the vasodilatory activities of Erythrityl tetranitrate.]
[S01AA17, erythromycin, The risk or severity of QTc prolongation and hypotension can be increased when Erythromycin is combined with Fluspirilene.]
[N05CD04, estazolam, The risk or severity of adverse effects can be increased when Estazolam is combined with Fluspirilene.]
[C01CA15, gepefrine, Fluspirilene may decrease the stimulatory activities of Gepefrine.]
[N05CM08, ethchlorvynol, The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Fluspirilene.]
[C01BD05, ibutilide, Ibutilide may increase the arrhythmogenic activities of Fluspirilene.]
[N04AA05, profenamine, Fluspirilene may increase the central nervous system depressant (CNS depressant) activities of Profenamine.]
[N03AD01, ethosuximide, Ethosuximide may increase the arrhythmogenic activities of Fluspirilene.]
[N03AB01, ethotoin, The risk or severity of adverse effects can be increased when Ethotoin is combined with Fluspirilene.]
[M01AC06, meloxicam, The risk or severity of hyperkalemia can be increased when Meloxicam is combined with Fluspirilene.]
[S01XA06, ethylmorphine, The risk or severity of adverse effects can be increased when Ethylmorphine is combined with Fluspirilene.]
[N01AX07, etomidate, The risk or severity of adverse effects can be increased when Etomidate is combined with Fluspirilene.]
[N05AE03, sertindole, The risk or severity of adverse effects can be increased when Fluspirilene is combined with Sertindole.]
[C01BA05, ajmaline, Ajmaline may increase the arrhythmogenic activities of Fluspirilene.]
[L04AD02, tacrolimus, Fluspirilene may increase the immunosuppressive activities of Tacrolimus.]
[J01MA08, fleroxacin, The risk or severity of QTc prolongation can be increased when Fleroxacin is combined with Fluspirilene.]
[R06AX11, astemizole, The risk or severity of QTc prolongation can be increased when Fluspirilene is combined with Astemizole.]
[R06AX12, terfenadine, The metabolism of Fluspirilene can be decreased when combined with Terfenadine.]
[N06AX12, bupropion, The risk or severity of adverse effects can be increased when Bupropion is combined with Fluspirilene.]
[N06AB08, fluvoxamine, The risk or severity of adverse effects can be increased when Fluspirilene is combined with Fluvoxamine.]
[C01BB03, tocainide, Tocainide may increase the arrhythmogenic activities of Fluspirilene.]
[C01BC08, encainide, Encainide may increase the arrhythmogenic activities of Fluspirilene.]
[L02AE02, leuprolide, The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Fluspirilene.]
[A02BA03, famotidine, The risk or severity of QTc prolongation can be increased when Famotidine is combined with Fluspirilene.]
[C08CA02, felodipine, Felodipine may increase the arrhythmogenic activities of Fluspirilene.]
[C08EA01, fendiline, Fluspirilene may increase the arrhythmogenic activities of Fendiline.]
[N03AX26, fenfluramine, The therapeutic efficacy of Fenfluramine can be decreased when used in combination with Fluspirilene.]
[M01AE04, fenoprofen, The risk or severity of hyperkalemia can be increased when Fenoprofen is combined with Fluspirilene.]
[N02AB03, fentanyl, The risk or severity of adverse effects can be increased when Fentanyl is combined with Fluspirilene.]
[R03CC02, albuterol, The risk or severity of QTc prolongation can be increased when Salbutamol is combined with Fluspirilene.]
[G04BD02, flavoxate, Fluspirilene may increase the central nervous system depressant (CNS depressant) activities of Flavoxate.]
[C01BC04, flecainide, Flecainide may increase the arrhythmogenic activities of Fluspirilene.]
[N02BG04, floctafenine, The risk or severity of hyperkalemia can be increased when Fluspirilene is combined with Floctafenine.]
[J02AC01, fluconazole, The metabolism of Fluspirilene can be decreased when combined with Fluconazole.]
[N07CA03, flunarizine, Flunarizine may increase the arrhythmogenic activities of Fluspirilene.]
[N05CD03, flunitrazepam, The risk or severity of adverse effects can be increased when Flunitrazepam is combined with Fluspirilene.]
[N06AA14, melitracen, The risk or severity of adverse effects can be increased when Fluspirilene is combined with Melitracen.]
[V03AZ01, ethanol, Fluspirilene may increase the central nervous system depressant (CNS depressant) activities of Ethanol.]
[L01BC02, fluorouracil, The risk or severity of QTc prolongation can be increased when Fluorouracil is combined with Fluspirilene.]
[N06AB03, fluoxetine, The risk or severity of serotonin syndrome can be increased when Fluspirilene is combined with Fluoxetine.]
[N05AF01, flupenthixol, The risk or severity of QTc prolongation can be increased when Fluspirilene is combined with Flupentixol.]
[N05AB02, fluphenazine, The risk or severity of adverse effects can be increased when Fluphenazine is combined with Fluspirilene.]
[N05CD01, flurazepam, The risk or severity of adverse effects can be increased when Flurazepam is combined with Fluspirilene.]
[S01BC04, flurbiprofen, The risk or severity of hyperkalemia can be increased when Flurbiprofen is combined with Fluspirilene.]
[S01AA13, fusidic acid, The metabolism of Fluspirilene can be decreased when combined with Fusidic acid.]
[J01MB04, pipemidic acid, The risk or severity of QTc prolongation can be increased when Pipemidic acid is combined with Fluspirilene.]
[N07XX04, sodium oxybate, The risk or severity of adverse effects can be increased when Fluspirilene is combined with Sodium oxybate.]
[M01AG01, mefenamic acid, The risk or severity of hyperkalemia can be increased when Mefenamic acid is combined with Fluspirilene.]
[C01DA05, pentaerythritol tetranitrate, Fluspirilene may increase the vasodilatory activities of Pentaerythritol tetranitrate.]
[M03AA01, alcuronium, Fluspirilene may increase the neuromuscular blocking activities of Alcuronium.]
[G01AX06, furazolidone, The risk or severity of adverse effects can be increased when Furazolidone is combined with Fluspirilene.]
[J05AE10, darunavir, The serum concentration of Fluspirilene can be increased when it is combined with Darunavir.]
[N05CF04, eszopiclone, The risk or severity of CNS depression can be increased when Fluspirilene is combined with Eszopiclone.]
[N05AL05, amisulpride, Fluspirilene may increase the antipsychotic activities of Amisulpride.]
[N06DA04, galantamine, The risk or severity of QTc prolongation can be increased when Galantamine is combined with Fluspirilene.]
[M03AC02, gallamine, Fluspirilene may increase the neuromuscular blocking activities of Gallamine.]
[C08DA02, gallopamil, Fluspirilene may increase the arrhythmogenic activities of Gallopamil.]
[N03AA04, barbexaclone, The metabolism of Fluspirilene can be increased when combined with Barbexaclone.]
[N06AX08, bifemelane, The risk or severity of adverse effects can be increased when Fluspirilene is combined with Bifemelane.]
[J01XA03, telavancin, The risk or severity of QTc prolongation can be increased when Fluspirilene is combined with Telavancin.]
[L02BX02, degarelix, The risk or severity of QTc prolongation can be increased when Degarelix is combined with Fluspirilene.]
[L01EA02, dasatinib, The risk or severity of QTc prolongation can be increased when Dasatinib is combined with Fluspirilene.]
[N04BC06, cabergoline, The risk or severity of adverse effects can be increased when Cabergoline is combined with Fluspirilene.]
[A10BJ02, liraglutide, The risk or severity of hypoglycemia can be increased when Fluspirilene is combined with Liraglutide.]
[A12AA10, calcium gluceptate, The therapeutic efficacy of Fluspirilene can be decreased when used in combination with Calcium glucoheptonate.]
[A12AA30, calcium levulinate, The therapeutic efficacy of Fluspirilene can be decreased when used in combination with Calcium levulinate.]
[N03AD03, methsuximide, Fluspirilene may increase the arrhythmogenic activities of Methsuximide.]
[N01AH02, alfentanil, The risk or severity of adverse effects can be increased when Alfentanil is combined with Fluspirilene.]
[L01EH01, lapatinib, The risk or severity of QTc prolongation can be increased when Lapatinib is combined with Fluspirilene.]
[A10BB01, glyburide, The risk or severity of hypoglycemia can be increased when Fluspirilene is combined with Glyburide.]
[A10BB09, gliclazide, The risk or severity of hypoglycemia can be increased when Fluspirilene is combined with Gliclazide.]
[A10BB07, glipizide, The risk or severity of hypoglycemia can be increased when Fluspirilene is combined with Glipizide.]
[N05CM18, dexmedetomidine, The risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Fluspirilene.]
[N05CE01, glutethimide, The risk or severity of adverse effects can be increased when Glutethimide is combined with Fluspirilene.]
[A06AX01, glycerin, The therapeutic efficacy of Glycerin can be decreased when used in combination with Fluspirilene.]
[C05AE01, nitroglycerin, Fluspirilene may increase the vasodilatory activities of Nitroglycerin.]
[C01BD04, dofetilide, Dofetilide may increase the arrhythmogenic activities of Fluspirilene.]
[C02CA04, doxazosin, The risk or severity of hypotension can be increased when Doxazosin is combined with Fluspirilene.]
[L01EX02, sorafenib, The risk or severity of QTc prolongation can be increased when Sorafenib is combined with Fluspirilene.]
[C07AB09, esmolol, Esmolol may increase the arrhythmogenic activities of Fluspirilene.]
[B01AA12, fluindione, The risk or severity of adverse effects can be increased when Fluspirilene is combined with Fluindione.]
[C09AA09, fosinopril, The risk or severity of hyperkalemia can be increased when Fosinopril is combined with Fluspirilene.]
[L02AE03, goserelin, The risk or severity of QTc prolongation can be increased when Goserelin is combined with Fluspirilene.]
[P01BX01, halofantrine, The risk or severity of QTc prolongation can be increased when Fluspirilene is combined with Halofantrine.]
[N05AD01, haloperidol, The risk or severity of QTc prolongation can be increased when Fluspirilene is combined with Haloperidol.]
[N01AB01, halothane, The risk or severity of adverse effects can be increased when Halothane is combined with Fluspirilene.]
[L02AE05, histrelin, The risk or severity of QTc prolongation can be increased when Histrelin is combined with Fluspirilene.]
[N05AH04, quetiapine, Fluspirilene may increase the central nervous system depressant (CNS depressant) activities of Quetiapine.]
[A10AD05, insulin aspart, human, The risk or severity of hypoglycemia can be increased when Fluspirilene is combined with Insulin aspart.]
[N02CX03, iprazochrome, The risk or severity of adverse effects can be increased when Fluspirilene is combined with Iprazochrome.]
[N05CA21, allobarbital, The risk or severity of adverse effects can be increased when Fluspirilene is combined with Allobarbital.]
[C09CA01, losartan, Losartan may increase the arrhythmogenic activities of Fluspirilene.]
[S01XA14, heparin, The risk or severity of hyperkalemia can be increased when Heparin is combined with Fluspirilene.]
[B05CB03, magnesium citrate, The risk or severity of hypotension can be increased when Magnesium citrate is combined with Fluspirilene.]
[A12CC03, magnesium gluconate, The risk or severity of hypotension can be increased when Magnesium gluconate is combined with Fluspirilene.]
[A07EC02, mesalamine, The risk or severity of hyperkalemia can be increased when Mesalazine is combined with Fluspirilene.]
[A12CD02, sodium monofluorophosphate, The therapeutic efficacy of Sodium fluorophosphate can be decreased when used in combination with Fluspirilene.]
[N05CA16, hexobarbital, The metabolism of Fluspirilene can be increased when combined with Hexobarbital.]
[C08CA10, nilvadipine, Fluspirilene may increase the arrhythmogenic activities of Nilvadipine.]
[M02AA26, nimesulide, Nimesulide may increase the arrhythmogenic activities of Fluspirilene.]
[R06AE06, oxatomide, The risk or severity of QTc prolongation can be increased when Fluspirilene is combined with Oxatomide.]
[C09AA04, perindopril, The risk or severity of hyperkalemia can be increased when Perindopril is combined with Fluspirilene.]
[C03AA03, hydrochlorothiazide, The risk or severity of QTc prolongation can be increased when Hydrochlorothiazide is combined with Fluspirilene.]
[R05DA03, hydrocodone, Fluspirilene may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.]
[B05XA17, potassium acetate, Potassium acetate may increase the hyperkalemic activities of Fluspirilene.]
[S01XA07, aluminum potassium sulfate, Potassium alum may increase the hyperkalemic activities of Fluspirilene.]
[A12BA02, potassium citrate, Potassium citrate may increase the hyperkalemic activities of Fluspirilene.]
[G04BD06, propiverine, Fluspirilene may increase the central nervous system depressant (CNS depressant) activities of Propiverine.]
[P01BA02, hydroxychloroquine, The risk or severity of QTc prolongation can be increased when Hydroxychloroquine is combined with Fluspirilene.]
[N05AX07, prothipendyl, The risk or severity of adverse effects can be increased when Fluspirilene is combined with Prothipendyl.]
[N05BB01, hydroxyzine, The risk or severity of QTc prolongation can be increased when Fluspirilene is combined with Hydroxyzine.]
[R02AX02, ibuprofen, The risk or severity of hyperkalemia can be increased when Ibuprofen is combined with Fluspirilene.]
[B05CB02, sodium citrate, Fluspirilene may increase the neurotoxic activities of Sodium citrate.]
[A06AD21, sodium tartrate, The therapeutic efficacy of Sodium tartrate can be decreased when used in combination with Fluspirilene.]
[N01AH03, sufentanil, The risk or severity of adverse effects can be increased when Sufentanil is combined with Fluspirilene.]
[N06AA02, imipramine, Fluspirilene may increase the central nervous system depressant (CNS depressant) activities of Imipramine.]
[L01CD01, paclitaxel, Paclitaxel may increase the neurotoxic activities of Fluspirilene.]
[H01BA04, terlipressin, The risk or severity of QTc prolongation can be increased when Terlipressin is combined with Fluspirilene.]
[M03BX02, tizanidine, The risk or severity of adverse effects can be increased when Tizanidine is combined with Fluspirilene.]
[C03BA11, indapamide, The risk or severity of QTc prolongation can be increased when Indapamide is combined with Fluspirilene.]
[S01BC01, indomethacin, The risk or severity of hyperkalemia can be increased when Indomethacin is combined with Fluspirilene.]
[C02CA02, indoramin, The risk or severity of hypotension can be increased when Indoramin is combined with Fluspirilene.]
[N06AX17, milnacipran, The risk or severity of adverse effects can be increased when Fluspirilene is combined with Milnacipran.]
[A03AA30, piperidolate, Fluspirilene may increase the central nervous system depressant (CNS depressant) activities of Piperidolate.]
[N01BB08, articaine, The risk or severity of adverse effects can be increased when Fluspirilene is combined with Articaine.]
[A10BH01, sitagliptin, The risk or severity of hypoglycemia can be increased when Fluspirilene is combined with Sitagliptin.]
[N05BA12, alprazolam, The risk or severity of adverse effects can be increased when Alprazolam is combined with Fluspirilene.]
[N05CH02, ramelteon, The risk or severity of adverse effects can be increased when Ramelteon is combined with Fluspirilene.]
[R06AE01, buclizine, Fluspirilene may increase the central nervous system depressant (CNS depressant) activities of Buclizine.]
[A10BH02, vildagliptin, The risk or severity of hypoglycemia can be increased when Fluspirilene is combined with Vildagliptin.]
[L01XX35, anagrelide, The risk or severity of QTc prolongation can be increased when Fluspirilene is combined with Anagrelide.]
[C07AA01, alprenolol, Alprenolol may increase the arrhythmogenic activities of Fluspirilene.]
[J05AF04, stavudine, Stavudine may increase the neurotoxic activities of Fluspirilene.]
[N06AA13, iprindole, The risk or severity of adverse effects can be increased when Fluspirilene is combined with Iprindole.]
[N06AF05, iproniazid, The risk or severity of adverse effects can be increased when Iproniazid is combined with Fluspirilene.]
[N05AA07, chlorproethazine, The risk or severity of adverse effects can be increased when Fluspirilene is combined with Chlorproethazine.]
[N06AF01, isocarboxazid, The risk or severity of adverse effects can be increased when Isocarboxazid is combined with Fluspirilene.]
[C09AA16, imidapril, The risk or severity of hyperkalemia can be increased when Fluspirilene is combined with Imidapril.]
[N01AB06, isoflurane, The risk or severity of adverse effects can be increased when Isoflurane is combined with Fluspirilene.]
[N04BX02, entacapone, The risk or severity of adverse effects can be increased when Entacapone is combined with Fluspirilene.]
[J04AC01, isoniazid, The metabolism of Fluspirilene can be decreased when combined with Isoniazid.]
[A10BJ01, exenatide, The risk or severity of hypoglycemia can be increased when Fluspirilene is combined with Exenatide.]
[C05AE02, isosorbide dinitrate, Fluspirilene may increase the vasodilatory activities of Isosorbide dinitrate.]
[N06AX18, reboxetine, The risk or severity of adverse effects can be increased when Reboxetine is combined with Fluspirilene.]
[N01AX03, ketamine, The risk or severity of adverse effects can be increased when Ketamine is combined with Fluspirilene.]
[C02KD01, ketanserin, The risk or severity of adverse effects can be increased when Fluspirilene is combined with Ketanserin.]
[J02AB02, ketoconazole, The metabolism of Fluspirilene can be decreased when combined with Ketoconazole.]
[N05AH03, olanzapine, Fluspirilene may increase the central nervous system depressant (CNS depressant) activities of Olanzapine.]
[M02AA10, ketoprofen, The risk or severity of hyperkalemia can be increased when Ketoprofen is combined with Fluspirilene.]
[R06AX25, mizolastine, The risk or severity of QTc prolongation can be increased when Fluspirilene is combined with Mizolastine.]
[N04BC09, rotigotine, Fluspirilene may increase the sedative activities of Rotigotine.]
[J01MB02, nalidixic acid, The risk or severity of QTc prolongation can be increased when Nalidixic acid is combined with Fluspirilene.]
[C07AG01, labetalol, The risk or severity of bradycardia can be increased when Fluspirilene is combined with Labetalol.]
[N04BB01, amantadine, The risk or severity of serotonin syndrome can be increased when Amantadine is combined with Fluspirilene.]
[A06AD11, lactulose, The therapeutic efficacy of Lactulose can be decreased when used in combination with Fluspirilene.]
[A06AX03, lubiprostone, The therapeutic efficacy of Lubiprostone can be decreased when used in combination with Fluspirilene.]
[N03AX18, lacosamide, The risk or severity of adverse effects can be increased when Fluspirilene is combined with Lacosamide.]
[N04BA01, levodopa, The risk or severity of adverse effects can be increased when Levodopa is combined with Fluspirilene.]
[S02DA01, lidocaine, Lidocaine may increase the arrhythmogenic activities of Fluspirilene.]
[C08EX01, lidoflazine, Fluspirilene may increase the arrhythmogenic activities of Lidoflazine.]
[J01FF02, lincomycin, Lincomycin may increase the neurotoxic activities of Fluspirilene.]
[C03DB01, amiloride, The risk or severity of hyperkalemia can be increased when Amiloride is combined with Fluspirilene.]
[N02CA07, lisuride, The risk or severity of adverse effects can be increased when Lisuride is combined with Fluspirilene.]
[N06AA07, lofepramine, The risk or severity of adverse effects can be increased when Fluspirilene is combined with Lofepramine.]
[A07DA03, loperamide, Loperamide may increase the arrhythmogenic activities of Fluspirilene.]
[N05BA06, lorazepam, The risk or severity of adverse effects can be increased when Lorazepam is combined with Fluspirilene.]
[C10AA02, lovastatin, The metabolism of Fluspirilene can be decreased when combined with Lovastatin.]
[N05AH01, loxapine, The risk or severity of adverse effects can be increased when Loxapine is combined with Fluspirilene.]
[B05XA11, magnesium chloride, The risk or severity of hypotension can be increased when Magnesium chloride is combined with Fluspirilene.]
[G04BX01, magnesium hydroxide, The risk or severity of hypotension can be increased when Magnesium hydroxide is combined with Fluspirilene.]
[A12CC10, magnesium oxide, The risk or severity of hypotension can be increased when Magnesium oxide is combined with Fluspirilene.]
[V04CC02, magnesium sulfate, The therapeutic efficacy of Fluspirilene can be increased when used in combination with Magnesium sulfate.]
[L01EA03, nilotinib, The metabolism of Fluspirilene can be decreased when combined with Nilotinib.]
[V04CX04, mannitol, The risk or severity of hyperkalemia can be increased when Mannitol is combined with Fluspirilene.]
[N06AA21, maprotiline, Fluspirilene may increase the central nervous system depressant (CNS depressant) activities of Maprotiline.]
[A08AA05, mazindol, The risk or severity of adverse effects can be increased when Mazindol is combined with Fluspirilene.]
[R06AE05, meclizine, The risk or severity of adverse effects can be increased when Meclizine is combined with Fluspirilene.]
[M02AA18, meclofenamic acid, The risk or severity of hyperkalemia can be increased when Meclofenamic acid is combined with Fluspirilene.]
[N05BA03, medazepam, The risk or severity of adverse effects can be increased when Fluspirilene is combined with Medazepam.]
[C01AA08, medigoxin, Fluspirilene may increase the arrhythmogenic activities of Metildigoxin.]
[A06AB07, cascara sagrada, The therapeutic efficacy of Frangula purshiana bark can be decreased when used in combination with Fluspirilene.]
[P01BC02, mefloquine, The risk or severity of QTc prolongation can be increased when Mefloquine is combined with Fluspirilene.]
[B01AB06, nadroparin, The risk or severity of hyperkalemia can be increased when Fluspirilene is combined with Nadroparin.]
[B01AB05, enoxaparin, The risk or severity of hyperkalemia can be increased when Enoxaparin is combined with Fluspirilene.]
[B01AB04, dalteparin, The risk or severity of hyperkalemia can be increased when Fluspirilene is combined with Dalteparin.]
[N05CH01, melatonin, The therapeutic efficacy of Fluspirilene can be decreased when used in combination with Melatonin.]
[N02AB02, meperidine, The risk or severity of adverse effects can be increased when Meperidine is combined with Fluspirilene.]
[C01CA11, mephentermine, Fluspirilene may decrease the stimulatory activities of Mephentermine.]
[N03AB04, mephenytoin, The risk or severity of adverse effects can be increased when Mephenytoin is combined with Fluspirilene.]
[N03AA01, mephobarbital, The metabolism of Fluspirilene can be increased when combined with Methylphenobarbital.]
[N01BB03, mepivacaine, The risk or severity of adverse effects can be increased when Mepivacaine is combined with Fluspirilene.]
[N05BC01, meprobamate, The risk or severity of adverse effects can be increased when Meprobamate is combined with Fluspirilene.]
[N02AX05, meptazinol, The risk or severity of adverse effects can be increased when Fluspirilene is combined with Meptazinol.]
[N05AC03, mesoridazine, The risk or severity of QTc prolongation can be increased when Mesoridazine is combined with Fluspirilene.]
[N05AX13, paliperidone, The risk or severity of QTc prolongation can be increased when Fluspirilene is combined with Paliperidone.]
[A10BA02, metformin, The risk or severity of hypoglycemia can be increased when Fluspirilene is combined with Metformin.]
[A04AA04, dolasetron, The risk or severity of QTc prolongation can be increased when Dolasetron is combined with Fluspirilene.]
[H01CB03, lanreotide, Fluspirilene may increase the bradycardic activities of Lanreotide.]
[N07BC02, methadone, The risk or severity of adverse effects can be increased when Methadone is combined with Fluspirilene.]
[N06BA03, methamphetamine, Fluspirilene may decrease the stimulatory activities of Metamfetamine.]
[A03AB07, methantheline, Fluspirilene may increase the central nervous system depressant (CNS depressant) activities of Methantheline.]
[R06AC05, methapyrilene, The risk or severity of adverse effects can be increased when Methapyrilene is combined with Fluspirilene.]
[N05CM01, methaqualone, The risk or severity of adverse effects can be increased when Methaqualone is combined with Fluspirilene.]
[N03AA30, metharbital, The risk or severity of adverse effects can be increased when Metharbital is combined with Fluspirilene.]
[G02CB05, metergoline, The risk or severity of adverse effects can be increased when Fluspirilene is combined with Metergoline.]
[H03BB02, methimazole, The metabolism of Fluspirilene can be decreased when combined with Methimazole.]
[M03BA03, methocarbamol, The risk or severity of adverse effects can be increased when Methocarbamol is combined with Fluspirilene.]
[N05CA15, methohexital, The metabolism of Fluspirilene can be increased when combined with Methohexital.]
[N02BG08, ziconotide, The risk or severity of CNS depression can be increased when Fluspirilene is combined with Ziconotide.]
[N05AA02, methotrimeprazine, Fluspirilene may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[N02BG09, methoxyflurane, The risk or severity of adverse effects can be increased when Methoxyflurane is combined with Fluspirilene.]
[A06AC06, methylcellulose, The therapeutic efficacy of Methylcellulose can be decreased when used in combination with Fluspirilene.]
[C02AB01, methyldopa, Methyldopa may increase the bradycardic activities of Fluspirilene.]
[V04CG05, methylene blue, Fluspirilene may increase the serotonergic activities of Methylene blue.]
[N06BA04, methylphenidate, The risk or severity of adverse effects can be increased when Fluspirilene is combined with Methylphenidate.]
[N03AF03, rufinamide, The risk or severity of adverse effects can be increased when Rufinamide is combined with Fluspirilene.]
[N05CE02, methyprylon, The risk or severity of adverse effects can be increased when Methyprylon is combined with Fluspirilene.]
[N02CA04, methysergide, The risk or severity of adverse effects can be increased when Methysergide is combined with Fluspirilene.]
[A03FA01, metoclopramide, The risk or severity of adverse effects can be increased when Metoclopramide is combined with Fluspirilene.]
[C07AB02, metoprolol, Metoprolol may increase the arrhythmogenic activities of Fluspirilene.]
[P01AB01, metronidazole, The risk or severity of QTc prolongation can be increased when Metronidazole is combined with Fluspirilene.]
[C01BB02, mexiletine, Mexiletine may increase the arrhythmogenic activities of Fluspirilene.]
[N06AX03, mianserin, The risk or severity of adverse effects can be increased when Mianserin is combined with Fluspirilene.]
[S02AA13, miconazole, The metabolism of Fluspirilene can be decreased when combined with Miconazole.]
[N02BB03, aminopyrine, The risk or severity of hyperkalemia can be increased when Aminophenazone is combined with Fluspirilene.]
[B01AB07, parnaparin, The risk or severity of hyperkalemia can be increased when Fluspirilene is combined with Parnaparin.]
[N05CD08, midazolam, The risk or severity of adverse effects can be increased when Midazolam is combined with Fluspirilene.]
[C01CA17, midodrine, Midodrine may increase the bradycardic activities of Fluspirilene.]
[G03XB01, mifepristone, The risk or severity of QTc prolongation can be increased when Fluspirilene is combined with Mifepristone.]
[B01AB10, tinzaparin, The risk or severity of hyperkalemia can be increased when Fluspirilene is combined with Tinzaparin.]
[A06AA01, mineral oil, The therapeutic efficacy of Mineral oil can be decreased when used in combination with Fluspirilene.]
[C09CA03, valsartan, The risk or severity of hyperkalemia can be increased when Valsartan is combined with Fluspirilene.]
[J01AA08, minocycline, Minocycline may increase the central nervous system depressant (CNS depressant) activities of Fluspirilene.]
[L01XX23, mitotane, The metabolism of Fluspirilene can be increased when combined with Mitotane.]
[N06BA12, lisdexamfetamine, Fluspirilene may decrease the stimulatory activities of Lisdexamfetamine.]
[N05AE02, molindone, The risk or severity of adverse effects can be increased when Molindone is combined with Fluspirilene.]
[C01BD01, amiodarone, The risk or severity of adverse effects can be increased when Amiodarone is combined with Fluspirilene.]
[N06AA09, amitriptyline, Fluspirilene may increase the central nervous system depressant (CNS depressant) activities of Amitriptyline.]
[N02AA01, morphine, The risk or severity of adverse effects can be increased when Morphine is combined with Fluspirilene.]
[A04AA05, palonosetron, The risk or severity of adverse effects can be increased when Palonosetron is combined with Fluspirilene.]
[G04BA01, ammonium chloride, The risk or severity of hyperkalemia can be increased when Fluspirilene is combined with Ammonium chloride.]
[L01EX03, pazopanib, The risk or severity of QTc prolongation can be increased when Fluspirilene is combined with Pazopanib.]
[M03AC03, vecuronium, Fluspirilene may increase the neuromuscular blocking activities of Vecuronium.]
[N05CA02, amobarbital, The metabolism of Fluspirilene can be increased when combined with Amobarbital.]
[P01BA06, amodiaquine, The risk or severity of QTc prolongation can be increased when Amodiaquine is combined with Fluspirilene.]
[G04CA04, silodosin, The risk or severity of hypotension can be increased when Silodosin is combined with Fluspirilene.]
[N06AA17, amoxapine, Fluspirilene may increase the central nervous system depressant (CNS depressant) activities of Amoxapine.]
[N03AB05, fosphenytoin, The metabolism of Fluspirilene can be increased when combined with Fosphenytoin.]
[C07AA12, nadolol, Nadolol may increase the arrhythmogenic activities of Fluspirilene.]
[N04BC04, ropinirole, The therapeutic efficacy of Ropinirole can be decreased when used in combination with Fluspirilene.]
[J01CF06, nafcillin, The therapeutic efficacy of Fluspirilene can be decreased when used in combination with Nafcillin.]
[C04AX21, nafronyl, The risk or severity of adverse effects can be increased when Fluspirilene is combined with Naftidrofuryl.]
[N02AF02, nalbuphine, The risk or severity of adverse effects can be increased when Nalbuphine is combined with Fluspirilene.]
[V03AB15, naloxone, The metabolism of Fluspirilene can be decreased when combined with Naloxone.]
[N07BB04, naltrexone, The risk or severity of serotonin syndrome can be increased when Naltrexone is combined with Fluspirilene.]
[N06BA01, amphetamine, Fluspirilene may decrease the stimulatory activities of Amphetamine.]
[M02AA12, naproxen, The risk or severity of hyperkalemia can be increased when Naproxen is combined with Fluspirilene.]
[A10BG01, troglitazone, The risk or severity of hypoglycemia can be increased when Fluspirilene is combined with Troglitazone.]
[N06AX21, duloxetine, The risk or severity of adverse effects can be increased when Fluspirilene is combined with Duloxetine.]
[N04BX01, tolcapone, The risk or severity of adverse effects can be increased when Tolcapone is combined with Fluspirilene.]
[S03AA01, neomycin, Neomycin may increase the neurotoxic activities of Fluspirilene.]
[N01AH06, remifentanil, The risk or severity of adverse effects can be increased when Remifentanil is combined with Fluspirilene.]
[A10BX02, repaglinide, The risk or severity of hypoglycemia can be increased when Fluspirilene is combined with Repaglinide.]
[C01CX08, levosimendan, Levosimendan may increase the arrhythmogenic activities of Fluspirilene.]
[N05AX14, iloperidone, The risk or severity of QTc prolongation can be increased when Fluspirilene is combined with Iloperidone.]
[J02AA01, amphotericin B, Fluspirilene may decrease the nephrotoxic activities of Amphotericin B.]
[N06AX23, desvenlafaxine, The risk or severity of adverse effects can be increased when Fluspirilene is combined with Desvenlafaxine.]
[C09CA07, telmisartan, The risk or severity of hyperkalemia can be increased when Telmisartan is combined with Fluspirilene.]
[N06AF02, nialamide, The risk or severity of adverse effects can be increased when Nialamide is combined with Fluspirilene.]
[C08CA04, nicardipine, Nicardipine may increase the arrhythmogenic activities of Fluspirilene.]
[C04AE02, nicergoline, The risk or severity of hypotension can be increased when Nicergoline is combined with Fluspirilene.]
[C08CA05, nifedipine, Nifedipine may increase the arrhythmogenic activities of Fluspirilene.]
[M02AA17, niflumic acid, The risk or severity of hyperkalemia can be increased when Niflumic acid is combined with Fluspirilene.]
[V03AB22, amyl nitrite, Fluspirilene may increase the vasodilatory activities of Amyl Nitrite.]
[C08CA06, nimodipine, Nimodipine may increase the arrhythmogenic activities of Fluspirilene.]
[C08CA07, nisoldipine, Nisoldipine may increase the arrhythmogenic activities of Fluspirilene.]
[N05CD02, nitrazepam, The risk or severity of adverse effects can be increased when Nitrazepam is combined with Fluspirilene.]
[C08CA08, nitrendipine, Nitrendipine may increase the arrhythmogenic activities of Fluspirilene.]
[J01XE01, nitrofurantoin, The risk or severity of hyperkalemia can be increased when Nitrofurantoin is combined with Fluspirilene.]
[N05CF03, zaleplon, The risk or severity of adverse effects can be increased when Zaleplon is combined with Fluspirilene.]
[N04BC05, pramipexole, The therapeutic efficacy of Pramipexole can be decreased when used in combination with Fluspirilene.]
[C02DD01, nitroprusside, Fluspirilene may increase the hypotensive activities of Nitroprusside.]
[N01AX13, nitrous oxide, The risk or severity of adverse effects can be increased when Fluspirilene is combined with Nitrous oxide.]
[N06AX04, nomifensine, The risk or severity of adverse effects can be increased when Nomifensine is combined with Fluspirilene.]
[S01AE02, norfloxacin, The risk or severity of QTc prolongation can be increased when Norfloxacin is combined with Fluspirilene.]
[N06AA10, nortriptyline, Fluspirilene may increase the central nervous system depressant (CNS depressant) activities of Nortriptyline.]
[G02CA02, nylidrin, Fluspirilene may increase the arrhythmogenic activities of Nylidrin.]
[B01AB08, reviparin, The risk or severity of hyperkalemia can be increased when Fluspirilene is combined with Reviparin.]
[H01CB02, octreotide, The serum concentration of the active metabolites of Octreotide can be increased when Octreotide is used in combination with Fluspirilene.]
[S02AA16, ofloxacin, The risk or severity of QTc prolongation can be increased when Ofloxacin is combined with Fluspirilene.]
[N06AA05, opipramol, The risk or severity of adverse effects can be increased when Fluspirilene is combined with Opipramol.]
[N02AA02, opium, The risk or severity of adverse effects can be increased when Fluspirilene is combined with Opium.]
[G02CB04, quinagolide, The therapeutic efficacy of Quinagolide can be decreased when used in combination with Fluspirilene.]
[G04CA02, tamsulosin, The risk or severity of hypotension can be increased when Tamsulosin is combined with Fluspirilene.]
[C01AC01, ouabain, The serum concentration of Ouabain can be increased when it is combined with Fluspirilene.]
[N05BA04, oxazepam, The risk or severity of adverse effects can be increased when Oxazepam is combined with Fluspirilene.]
[J01MB05, oxolinic acid, The risk or severity of QTc prolongation can be increased when Oxolinic acid is combined with Fluspirilene.]
[C07AA02, oxprenolol, Oxprenolol may increase the arrhythmogenic activities of Fluspirilene.]
[N02AA05, oxycodone, The risk or severity of adverse effects can be increased when Oxycodone is combined with Fluspirilene.]
[N02AA11, oxymorphone, The risk or severity of adverse effects can be increased when Oxymorphone is combined with Fluspirilene.]
[N05AE01, oxypertine, The risk or severity of adverse effects can be increased when Fluspirilene is combined with Oxypertine.]
[S01BC02, oxyphenbutazone, The risk or severity of hyperkalemia can be increased when Oxyphenbutazone is combined with Fluspirilene.]
[A03AB03, oxyphenonium, Fluspirilene may increase the central nervous system depressant (CNS depressant) activities of Oxyphenonium.]
[H01BB02, oxytocin, The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Fluspirilene.]
[N05AH05, asenapine, The risk or severity of QTc prolongation can be increased when Fluspirilene is combined with Asenapine.]
[B01AB09, danaparoid, The risk or severity of hyperkalemia can be increased when Fluspirilene is combined with Danaparoid.]
[N02AX06, tapentadol, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Fluspirilene.]
[M03AC01, pancuronium, Fluspirilene may increase the central nervous system depressant (CNS depressant) activities of Pancuronium.]
[G04BE02, papaverine, The risk or severity of QTc prolongation can be increased when Papaverine is combined with Fluspirilene.]
[N05CC05, paraldehyde, Fluspirilene may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.]
[C02KC01, pargyline, The risk or severity of adverse effects can be increased when Pargyline is combined with Fluspirilene.]
[J01MA03, pefloxacin, The risk or severity of QTc prolongation can be increased when Pefloxacin is combined with Fluspirilene.]
[G04BD11, fesoterodine, Fluspirilene may increase the central nervous system depressant (CNS depressant) activities of Fesoterodine.]
[C07AA23, penbutolol, The risk or severity of bradycardia can be increased when Fluspirilene is combined with Penbutolol.]
[N05AG03, penfluridol, Fluspirilene may increase the arrhythmogenic activities of Penfluridol.]
[N02AD01, pentazocine, The risk or severity of adverse effects can be increased when Pentazocine is combined with Fluspirilene.]
[N05CA01, pentobarbital, The metabolism of Fluspirilene can be increased when combined with Pentobarbital.]
[N05AB10, perazine, The risk or severity of adverse effects can be increased when Fluspirilene is combined with Perazine.]
[N04BC02, pergolide, The risk or severity of adverse effects can be increased when Pergolide is combined with Fluspirilene.]
[C08EX02, perhexiline, Perhexiline may increase the arrhythmogenic activities of Fluspirilene.]
[N05AB03, perphenazine, The risk or severity of adverse effects can be increased when Perphenazine is combined with Fluspirilene.]
[N02AD02, phenazocine, The risk or severity of adverse effects can be increased when Fluspirilene is combined with Phenazocine.]
[N06AF03, phenelzine, The risk or severity of adverse effects can be increased when Phenelzine is combined with Fluspirilene.]
[A10BA01, phenformin, The risk or severity of hypoglycemia can be increased when Fluspirilene is combined with Phenformin.]
[B01AA02, phenindione, The risk or severity of adverse effects can be increased when Fluspirilene is combined with Phenindione.]
[R06AB05, pheniramine, The risk or severity of QTc prolongation can be increased when Pheniramine is combined with Fluspirilene.]
[N03AA02, phenobarbital, The metabolism of Fluspirilene can be increased when combined with Phenobarbital.]
[A06AB01, oxyphenisatin, The therapeutic efficacy of Oxyphenisatin can be decreased when used in combination with Fluspirilene.]
[N01AH04, phenoperidine, The risk or severity of adverse effects can be increased when Fluspirilene is combined with Phenoperidine.]
[C04AX02, phenoxybenzamine, The risk or severity of hypotension can be increased when Phenoxybenzamine is combined with Fluspirilene.]
[B01AA04, phenprocoumon, The risk or severity of adverse effects can be increased when Fluspirilene is combined with Phenprocoumon.]
[A08AA01, phentermine, Fluspirilene may decrease the stimulatory activities of Phentermine.]
[V03AB36, phentolamine, The risk or severity of hypotension can be increased when Phentolamine is combined with Fluspirilene.]
[M02AA01, phenylbutazone, The risk or severity of hyperkalemia can be increased when Phenylbutazone is combined with Fluspirilene.]
[S01GA05, phenylephrine, The risk or severity of hypertension can be decreased when Fluspirilene is combined with Phenylephrine.]
[N03AB02, phenytoin, The metabolism of Fluspirilene can be increased when combined with Phenytoin.]
[S01AE05, levofloxacin, The risk or severity of QTc prolongation can be increased when Levofloxacin is combined with Fluspirilene.]
[C08CX01, mibefradil, Mibefradil may increase the arrhythmogenic activities of Fluspirilene.]
[N05AG02, pimozide, The risk or severity of QTc prolongation can be increased when Fluspirilene is combined with Pimozide.]
[C07AA03, pindolol, The risk or severity of bradycardia can be increased when Fluspirilene is combined with Pindolol.]
[J05AE01, saquinavir, The metabolism of Fluspirilene can be decreased when combined with Saquinavir.]
[N05AC04, pipothiazine, The risk or severity of adverse effects can be increased when Pipotiazine is combined with Fluspirilene.]
[C09CA02, eprosartan, The risk or severity of hyperkalemia can be increased when Eprosartan is combined with Fluspirilene.]
[A02BX03, pirenzepine, Fluspirilene may increase the central nervous system depressant (CNS depressant) activities of Pirenzepine.]
[N04BC08, piribedil, The therapeutic efficacy of Piribedil can be decreased when used in combination with Fluspirilene.]
[N02AC03, pirinitramide, The risk or severity of adverse effects can be increased when Fluspirilene is combined with Piritramide.]
[S01BC06, piroxicam, The risk or severity of hyperkalemia can be increased when Piroxicam is combined with Fluspirilene.]
[J01MA11, grepafloxacin, The risk or severity of QTc prolongation can be increased when Fluspirilene is combined with Grepafloxacin.]
[N02CX01, pizotyline, Fluspirilene may increase the central nervous system depressant (CNS depressant) activities of Pizotifen.]
[J05AG02, delavirdine, The metabolism of Fluspirilene can be decreased when combined with Delavirdine.]
[C09CA04, irbesartan, The risk or severity of hyperkalemia can be increased when Irbesartan is combined with Fluspirilene.]
[N05CA22, proxibarbal, The risk or severity of adverse effects can be increased when Fluspirilene is combined with Proxibarbal.]
[A10BG02, rosiglitazone, The risk or severity of hypoglycemia can be increased when Fluspirilene is combined with Rosiglitazone.]
[A06AD15, polyethylene glycols, The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Fluspirilene.]
[A03AE01, alosetron, The risk or severity of adverse effects can be increased when Alosetron is combined with Fluspirilene.]
[S03AA03, polymyxin B, Fluspirilene may increase the neurotoxic activities of Polymyxin B.]
[J05AE03, ritonavir, The serum concentration of Fluspirilene can be increased when it is combined with Ritonavir.]
[A10BH03, saxagliptin, The risk or severity of hypoglycemia can be increased when Fluspirilene is combined with Saxagliptin.]
[B05XA01, potassium chloride, Potassium chloride may increase the hyperkalemic activities of Fluspirilene.]
[V03AB21, potassium iodide, Potassium Iodide may increase the hyperkalemic activities of Fluspirilene.]
[A10AD04, insulin lispro, The risk or severity of hypoglycemia can be increased when Fluspirilene is combined with Insulin lispro.]
[C07AB01, practolol, Practolol may increase the arrhythmogenic activities of Fluspirilene.]
[C01BA08, prajmaline, Fluspirilene may increase the arrhythmogenic activities of Prajmaline.]
[N05BA11, prazepam, The risk or severity of adverse effects can be increased when Prazepam is combined with Fluspirilene.]
[C02CA01, prazosin, The risk or severity of hypotension can be increased when Prazosin is combined with Fluspirilene.]
[R06AX05, antazoline, The risk or severity of QTc prolongation can be increased when Fluspirilene is combined with Antazoline.]
[C01DX02, prenylamine, Prenylamine may increase the arrhythmogenic activities of Fluspirilene.]
[N01BB04, prilocaine, The risk or severity of adverse effects can be increased when Prilocaine is combined with Fluspirilene.]
[P01BA03, primaquine, The risk or severity of QTc prolongation can be increased when Primaquine is combined with Fluspirilene.]
[N03AA03, primidone, The metabolism of Fluspirilene can be increased when combined with Primidone.]
[C10AX02, probucol, The risk or severity of QTc prolongation can be increased when Probucol is combined with Fluspirilene.]
[C01BA02, procainamide, Procainamide may increase the arrhythmogenic activities of Fluspirilene.]
[S01HA05, procaine, The risk or severity of adverse effects can be increased when Procaine is combined with Fluspirilene.]
[L01XB01, procarbazine, The risk or severity of adverse effects can be increased when Procarbazine is combined with Fluspirilene.]
[N05AB04, prochlorperazine, The risk or severity of QTc prolongation can be increased when Prochlorperazine is combined with Fluspirilene.]
[N04AA04, procyclidine, Fluspirilene may increase the central nervous system depressant (CNS depressant) activities of Procyclidine.]
[N05AA03, promazine, Fluspirilene may increase the central nervous system depressant (CNS depressant) activities of Promazine.]
[R06AD02, promethazine, Fluspirilene may increase the central nervous system depressant (CNS depressant) activities of Promethazine.]
[C01BC03, propafenone, Propafenone may increase the arrhythmogenic activities of Fluspirilene.]
[N01AX04, propanidid, The risk or severity of adverse effects can be increased when Fluspirilene is combined with Propanidid.]
[A03AB05, propantheline, Fluspirilene may increase the central nervous system depressant (CNS depressant) activities of Propantheline.]
[N05AC01, periciazine, The risk or severity of hypotension can be increased when Periciazine is combined with Fluspirilene.]
[N05CM06, propiomazine, Fluspirilene may increase the central nervous system depressant (CNS depressant) activities of Propiomazine.]
[L01XH02, romidepsin, The risk or severity of QTc prolongation can be increased when Fluspirilene is combined with Romidepsin.]
[N01AX10, propofol, The risk or severity of adverse effects can be increased when Propofol is combined with Fluspirilene.]
[N02AC04, propoxyphene, The risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Fluspirilene.]
[C07AA05, propranolol, Propranolol may increase the arrhythmogenic activities of Fluspirilene.]
[C01AB01, proscillaridin, The serum concentration of Proscillaridin can be increased when it is combined with Fluspirilene.]
[N02CC04, rizatriptan, The risk or severity of adverse effects can be increased when Rizatriptan is combined with Fluspirilene.]
[N06AA11, protriptyline, The risk or severity of adverse effects can be increased when Protriptyline is combined with Fluspirilene.]
[R01BA02, pseudoephedrine, Fluspirilene may decrease the stimulatory activities of Pseudoephedrine.]
[N05AX12, aripiprazole, Fluspirilene may increase the central nervous system depressant (CNS depressant) activities of Aripiprazole.]
[A03AB15, diphemanil, Fluspirilene may increase the central nervous system depressant (CNS depressant) activities of Diphemanil.]
[A03AB09, isopropamide, Fluspirilene may increase the central nervous system depressant (CNS depressant) activities of Isopropamide.]
[S01FA03, methscopolamine, Fluspirilene may increase the central nervous system depressant (CNS depressant) activities of Methscopolamine.]
[N05CA07, talbutal, The risk or severity of adverse effects can be increased when Talbutal is combined with Fluspirilene.]
[N05CA09, vinbarbital, The risk or severity of adverse effects can be increased when Fluspirilene is combined with Vinbarbital.]
[N05BB02, captodiamine, The risk or severity of adverse effects can be increased when Fluspirilene is combined with Captodiame.]
[M03BA04, styramate, The risk or severity of adverse effects can be increased when Fluspirilene is combined with Styramate.]
[P02CC01, pyrantel, The risk or severity of adverse effects can be increased when Fluspirilene is combined with Pyrantel.]
[A12BA05, potassium gluconate, Potassium gluconate may increase the hyperkalemic activities of Fluspirilene.]
[R06AC01, pyrilamine, The risk or severity of adverse effects can be increased when Fluspirilene is combined with Mepyramine.]
[C01BA01, quinidine, Quinidine may increase the arrhythmogenic activities of Fluspirilene.]
[P01BC01, quinine, The risk or severity of QTc prolongation can be increased when Fluspirilene is combined with Quinine.]
[C02AA01, rescinnamine, The risk or severity of hyperkalemia can be increased when Rescinnamine is combined with Fluspirilene.]
[C02AA02, reserpine, The risk or severity of adverse effects can be increased when Reserpine is combined with Fluspirilene.]
[J04AB02, rifampin, The metabolism of Fluspirilene can be increased when combined with Rifampicin.]
[N06AX01, 5-hydroxytryptophan, The risk or severity of adverse effects can be increased when Oxitriptan is combined with Fluspirilene.]
[J01FA06, roxithromycin, The risk or severity of QTc prolongation can be increased when Roxithromycin is combined with Fluspirilene.]
[N02BA05, salicylamide, The risk or severity of hyperkalemia can be increased when Fluspirilene is combined with Salicylamide.]
[A07EC01, sulfasalazine, The risk or severity of hyperkalemia can be increased when Sulfasalazine is combined with Fluspirilene.]
[S01BC08, salicylic acid, The risk or severity of hyperkalemia can be increased when Salicylic acid is combined with Fluspirilene.]
[S01FA02, scopolamine, Fluspirilene may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[N05CA06, secobarbital, The metabolism of Fluspirilene can be increased when combined with Secobarbital.]
[N04BD01, selegiline, The risk or severity of adverse effects can be increased when Selegiline is combined with Fluspirilene.]
[V04CC01, sorbitol, The therapeutic efficacy of Sorbitol can be decreased when used in combination with Fluspirilene.]
[C07AA07, sotalol, Sotalol may increase the arrhythmogenic activities of Fluspirilene.]
[C03DA01, spironolactone, The risk or severity of hyperkalemia can be increased when Spironolactone is combined with Fluspirilene.]
[C01DA14, isosorbide mononitrate, Fluspirilene may increase the vasodilatory activities of Isosorbide mononitrate.]
[H02CA04, levoketoconazole, The metabolism of Fluspirilene can be decreased when combined with Levoketoconazole.]
[M01AE11, tiaprofenic acid, The risk or severity of hyperkalemia can be increased when Tiaprofenic acid is combined with Fluspirilene.]
[A12AA11, calcium pangamate, The therapeutic efficacy of Fluspirilene can be decreased when used in combination with Calcium pangamate.]
[R03BB01, ipratropium bromide, Fluspirilene may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
